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 The chemical diversification of natural products provides a robust and general method for 
creation of stereochemically complex and structurally diverse small molecules. The resulting 
compounds have physicochemical traits different from those in most screening collections, and 
as such are a rich source for biological discovery. Herein, we subject the complexity-to-diversity 
library of compounds to an anticancer phenotypic screen. This effort resulted in identification of 
an active class of compounds derived from pleuromutilin natural product. Biological evaluation 
identified the novel compound ferroptocide, a small molecule that rapidly and robustly induces 
ferroptotic death of cancer cells. Target identification efforts and CRISPR knockout studies 
reveal that ferroptocide has a different target from other known pro-ferroptotic agents; it is an 
inhibitor of thioredoxin, a key component of the thioredoxin antioxidant system in the cell.  
Ferroptocide shows the ability to positively modulate the immune system in a murine model of 
breast cancer and will be a useful tool to study the utility of pro-ferroptotic agents for treatment 
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Chapter 1: Ferroptosis: Current Landscape 
1.1 Modes of cell death  
Cell death is, counterintuitively, an essential step in the continued life of an organism. 
Because of this critical role, it is a detailed genetic process carried through specific cellular 
mechanisms targeting harmful and irreversibly damaged cells. Cells die either via accidental cell 
death (ACD) due to severe external stimuli such as physical, chemical, and mechanical insults, 
or regulated cell death (RCD), which relies on defined intrinsic signaling mechanisms and can be 
modulated in a pharmacological or genetic manner.4  
Regulated cell death was synonymous for decades with an apoptotic death phenotype; 
however, other regulated forms of cell death with characteristic molecular mechanisms and 
morphological features have recently 
emerged. Due to distinctive 
morphological changes, RCD can be 
categorized into three types (Fig. 1.1): 
Type I is referred to as apoptosis 
(characterized by membrane blebbing, 
chromatin condensation, nuclear 
fragmentation, caspase activation, 
cytochrome c release, cleavage of PARP, etc.), Type II is referred to as autophagy (extensive 
cytoplasmic vacuolization, phagocytosis, and lysosomal degradation), and Type III is referred to 
as necrosis (membrane rupturing and release of cellular contents in the extracellular matrix, Fig 
1.1).4,7 Such modes of cell death reside between the two cell death extremes (apoptosis and 
Figure 1.1. Spectrum of cell death. Cell death is categorized in 




necrosis) depending on their caspase dependency as shown in Figure 1.2. The focus of this 
chapter will be on ferroptosis, its relevant pathways, activators and inhibitors, as well as its 
evolutionary role in disease. 
 
1.2 Ferroptosis RCD and its pathways 
1.2.1 Hallmarks of ferroptosis 
Coined in 2012, ferroptosis is a newly discovered mode of regulated cell death that relies on 
accumulation of iron-dependent lipid peroxidation to lethal levels resulting in cell demise.3,6,8,9 
This ferroptotic death phenotype involves unique morphological, biochemical, and genetic core 
features that are distinctive from any other form of cell death. Indeed, the cell death committee 
has recently highlighted these key characteristics such as: accumulation of general reactive 
oxygen species (ROS), iron-dependent lipid ROS, and protection against ferroptotic cell death 
via iron-chelators (deferoxamine), lipophilic antioxidants (trolox, α-tocopherol), ferroptosis-
specific inhibitors (ferrostain-1, liproxstatin), and inhibitors of lipid peroxidation.7 These 
guidelines are highly recommended in mechanistic studies aimed at elucidating the mode of cell 
death of small molecules suspected of displaying a ferroptotic profile.  
Figure 1.2. Various types of cell death based on caspase dependency. Apoptosis and 
pyroptosis are the only caspase dependent forms of cell death. 
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Comparison of the cell death hallmarks between ferroptosis and other RCDs (apoptosis, 
necroptosis, autophagy, and parthanatos) result in no overlap between these pathways, 
emphasizing the uniqueness of ferroptosis as a regulated form of cell death (Table 1.1). It is 
important to note that some of these hallmarks (phosphatidylserine exposure, executioner 
caspase -3, -7, -9 activation, membrane depolarization, DNA damage, etc.) offer invaluable 
information in tracking cell death in vivo, and current efforts are focusing on developing 
detection agents for use of these biomarkers in the clinic.10 Unfortunately, to date, there are no 
suitable biomarkers of ferroptosis in vivo. These markers are mainly limited to assessing the 
abundance of NADP(H)11, mRNA levels of prostaglandin E synthase 2 (PTGES2)12 and ChaC 
glutathionespecific gamma-glutamylcyclotransferase 1 (CHAC1) in cells, which can predict 
sensitivity to ferroptosis. Further in-depth studies and biocompatible probes are needed to 
identify predictable hallmarks of ferroptosis, which could be necessary to bridge the gap between 














Table 1.1. A comparison of features of apoptotic and non-apoptotic forms of cell death. Abbreviations: TNF, 
tumor necrosis factor; MMP, mitochondrial transmembrane potential; MOMP, mitochondrial outer membrane 
potential; TRADD, tumor necrosis factor receptor type 1-associated DEATH domain protein; FADD, Fas-
associated protein with death domain; Atg, autophagy-related genes; PARP-1, poly (ADP-ribose) polymerase 1; 
GCL, glutamate-cysteine ligase. This table is adopted with permission from Springer Nature (2016).3  
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1.2.2 Pathways implicated in ferroptosis 
The current understanding in the field outlines two main pathways as key inducers of 
ferroptosis: 1) inhibition of system XC
-, 2) direct or indirect inactivation of a glutathione-
dependent enzyme, GPX4, as shown in Figure 1.3. Critical processes of these routes include 
glutathione biosynthesis, amino acid-, lipid-, and iron-metabolism. In the advent of system XC
-
failure, cells use the transsulfuration pathway to biosynthesize cysteine from methionine, 
bypassing the system XC
- and displaying resistance to ferroptosis-inducing compounds.6,13 A 
genome-wide siRNA screen identified cysteinyl-t-RNA synthase (CARS) as a genetic 
suppressor, whose loss results in upregulation of the transsulfuration pathway, inhibition of lipid 
ROS generation, leading to resistance to ferroptosis, and thus linking transsulfuration to this 
mode of cell death.14,15  
Lipid metabolism is another essential process in the execution of ferroptosis. The presence of 
Figure 1.3. Inhibition of system XC-, and GPX4 results in generation of iron-dependent lipid 





labile bis-allylic hydrogens in polyunsaturated fatty acids (PUFAs) renders them susceptible to 
enzymatic and non-enzymatic oxidation that results in lipid peroxidation and generation of 
ferroptotic death signals.6,16 Free PUFAs must be esterified to membrane phospholipids and 
undergo oxidation to signal ferroptosis.17 Importantly, abundance and localization of highly 
oxidizable PUFAs is correlated with sensitivity to ferroptosis-inducing compounds. The most 
commonly depleted PUFAs in ferroptotic cells are arachidonic acid (AA) and adrenic acid 
phospholipids supported by lipidomic studies.18-20   
Furthermore, enzymes involved in PUFA-biosynthesis and remodeling such as acyl-coA 
synthetase long chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 
(LPCAT3) can modulate a response to ferroptosis. Genetic knockdown of these enzymes confers 
resistance to ferroptosis while treatment with excess AA increases ferroptotic sensitivity.17,21,22 
Other enzymes that mediate induction of ferroptosis include lipoxygenase (LOX) and 
cyclooxygenase (COX), which directly catalyze the formation of lipid peroxides. Genetic 
knockdown23 and small molecule inhibition of LOXs24 such as LOX-12 and LOX-15 result in 
Figure 1.4. Relevant pathways involved in ferroptosis. Images are adapted with permission from 
Stockwell and coworkers.6 
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increased resistance to compound-induced ferroptosis. Taken together, these studies emphasize 
the importance of lipids and their relevant enzymes in modulation of this form of cell death. 
In addition, glutamine can trigger ferroptosis due to glutaminolysis. This process enables 
glutamine degradation, which is a carbon-source for the tricarboxylic acid (TCA) cycle and lipid 
biosynthesis, rendering it invaluable in ferroptosis.3,6 To support this hypothesis, Gao and 
coworkers demonstrated that α-ketoglutarate, a product of the TCA cycle can overcome the need 
for glutamine in ferroptosis.25 The only other enzyme of glutaminolysis that is required in 
ferroptosis is mitochondrial glutaminase GLS2, which catalyzes the first step of 
glutaminolysis,6,25   thus connecting this process to ferroptotic cell death.  
Another important driver of ferroptosis is the mevalonate pathway (Fig 1.4). This pathway 
plays a vital role in selenocysteine synthesis—required for GPX4 maturation, and production of 
coenzyme Q10 (CoQ10), which is an endogenous inhibitor of ferroptosis as observed from its 
antioxidant function in membranes.26,27 A typical selenoprotein, GPX4, contains a selenocysteine 
in its catalytic site and uses it to detoxify lipid peroxides. The mevalonate pathway is the primary 
source of generation of isopentenyl pyrophosphate (IPP), which regulates a Sec transfer RNA 
overseeing the maturation of GPX4.26,28,29 In addition, a ferroptosis-inducing compound (FIN56) 
was shown to decrease the levels of coenzyme Q10, a mevalonate-derived lipophilic antioxidant, 
further establishing the interplay between the mevalonate pathway and ferroptosis.27  
1.2.3 Execution of ferroptosis 
   Ferroptotic cell death is likely executed via fragmentation of lipid peroxides into 
electrophilic reactive species such as aldehydes and conjugate acceptors that can covalently react 
with plasma membrane proteins, other essential proteins, and nucleic acids. Sequencing of 
erastin-resistant cells revealed upregulation of aldo-keto reductase family 1-member C (AKR1C) 
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family genes, which convert reactive end-products of lipid peroxidation to unreactive species, 
thus supporting this hypothesis.30,31 Furthermore, NRF2 has been shown to specifically modulate 
the gene transcription of this family gene among other functions, and promote resistance to 
ferroptosis.32-34   
Another key player in execution of ferroptosis is iron. Iron storage, transport, and metabolism 
in cells together with the pathways that tightly regulate them govern the sensitivity to 
ferroptosis.35 In addition, the pool of free labile iron in cells can generate ROS via the Fenton 
reaction.35,36 This pool is modulated by ferritin, an iron storage protein, whose degradation via 
ferritinophagy increases iron availability and renders cells sensitive to ferroptosis (Fig. 1.5).37,38 
Iron chelation by the addition of exogeneous small molecules or genetic alterations of iron-
dependent enzymes blocks ferroptosis and rescues cells from death, thus emphasizing the 
importance of this element in the ferroptotic cell death modality. 
1.3 Small molecule inducers and inhibitors of ferroptosis 
1.3.1 Inducers of ferroptosis 
All reported ferroptosis inducers share one common feature, their ability to breach the 
glutathione-dependent lipid peroxidation defense network in cells. Nonetheless, as eluded to 
previously, they can be categorized into two main classes: Class I includes compounds that cause 
inhibition of system XC
-, which results in depletion of glutathione, and Class II activators that 
cause inactivation of GPX4 either via direct alkylation [RSL3, ML162] or indirectly due to 
degradation of GPX4 (FIN56) or inhibition of its enzymatic activity [FINO2] shown in Figure 
1.5. Dixon and coworkers were the first to assess induction of ferroptosis with small molecule 
compounds.8 The genesis of this work stemmed from identification of small molecules that were 
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selectively lethal for RAS mutant tumor cells. This promising work captured the interest in the 
field given that 30% of cancers possess mutations of the RAS family of small GTPases.8,39  
A high throughput screen for compounds that displayed synthetic lethality with oncogenic 
RAS (HRASG12V) discovered erastin (Fig. 1.5 A) in engineered cell lines of fibroblasts (BJ-
TERT/LT/ST/RASV12).40,41 These cells (BJ) were engineered to express in a systematic fashion 
the catalytic subunit of human telomerase (hTERT), the SV40 large T and small T antigens (LT 
and ST), and the oncogenic allele of HRAS (HRASG12V), thus enabling generation of isogenic 
cell line pairs. Mechanistic studies elucidated mitochondrial voltage dependent anion channels 
(VDAC) as direct targets of erastin while its ferroptotic profile was attributed to inhibition of 
system XC
-, that leading to depletion of glutathione.8,41 Given this activity, erastin is considered a 
class I ferroptotic inducer. 
RSL342 and ML16243 (Fig. 1.5 B) are class II inhibitors that were identified in two separate 
synthetic lethal screens in the same BJ cell system, but displaying potency and selectivity in 
HRAS and KRAS mutant cancer cells. Counter-screening with bioactive compounds that 
suppressed cell death induced by erastin and RSL3 elucidated details of the mechanism of action 
of these compounds and revealed the importance of cellular iron in promoting selective lethality 
with oncogenic RAS. Notably, GPX4 was identified as the direct target of the RSL3 covalent 
inhibitor in a subsequent study, which established the role of GPX4 as a central regulator of 
ferroptosis.12   
Further efforts utilizing modulatory profiling to map cell death and identify small molecules 
with regulated non-apoptotic death phenotype in HT-1080 and engineered BJ cells, discovered 
FIN56 as a new type of class II ferroptosis activators (Fig. 1.5 B).27 In contrast to erastin and 
RSL3, FIN56 causes degradation of GPX4 enzyme via modulation of squalene synthase of the 
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mevalonate pathway. This study was pivotal in elucidating the role of lipid metabolism in 
ferroptosis and the consequences of its dysregulation in cells.  
Additionally, a successful collaboration between the Woerpel laboratory and the National 
Cancer Institute (NCI) identified another class II inducer, FINO2, via NCI’s in vitro cell 
screening project (Fig. 1.5 B).44 This small molecule  displayed a non-apoptotic phenotype that 
was determined to be ferroptotic in nature without modulating the known protein targets of 
ferroptosis. A follow up study unraveled the complex role of this small molecule in ferroptosis, 
encompassing the indirect inhibition of GPX4 enzymatic activity and direct oxidation of iron, 
thus resulting in generation of massive lipid peroxidation.45 
Despite our understanding of ferroptosis as a mode of regulated cell death being in its 
infancy, to date there have been at least seven ferroptosis-inducing small molecules introduced to 
the chemical biologist’s tool box. These probes have been instrumental in discovering many of 
the key ferroptotic pathways and central regulators mentioned above, which can be grouped in 
one overarching theme—glutathione-dependent lipid peroxidation. Yet, many uncharted 
territories including its relevance to other cellular antioxidant systems exist in ferroptosis, and 
Figure 1.5. Current ferroptosis-inducing compounds can be categorized in: (A) class I 
inhibitors that cause depletion of glutathione (B) class II inhibitors that inactivate directly or 
indirectly the glutathione-dependent enzyme, GPX4. 
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discovery of novel ferroptosis-inducing tool compounds is needed as they can help uncover new 
biology and molecular pathways relevant to this cell death modality.  
1.3.2 Inhibitors of ferroptosis 
Multiple reports have also investigated the pharmacological inhibition of ferroptosis via 
small molecule compounds. These molecules serve as protectants against ferroptosis and are 
crucial tools for investigating ferroptosis-inducing compounds (Fig. 1.6). These inhibitors act as 
iron chelators (deferoxamine) or antioxidants (ferrostatin-1, liproxstatin-1, Trolox, vitamin E) 
and are readily available for cell studies. Deferoxamine is a membrane-impermeable compound 
that localizes in lysosomes via endocytosis and chelates lysosomal iron. The current hypothesis 
is that lysosomal iron is directed to other compartment of the cells and disruption of its delivery 
results in reduction of the overall iron levels and thus prevention of ferroptosis.3 
Despite the ability of various compounds to act as radical scavengers, in fact not all can 
rescue cells from ferroptotic cell death. A combination of lipophilic antioxidants (vitamin E and 
Trolox) and ferroptosis-specific inhibitors is needed to protect cells from the lethal ferroptotic 
phenotype. Assessment of cell death using this combination is required to provide sufficient 
evidence in determining if a novel compound triggers ferroptosis.  
   
Figure 1.6. A limited series of compounds are known to inhibit ferroptosis. Deferoxamine is an iron chelator while 




In conclusion, after surveying the ferroptosis landscape of its inducers and inhibitors, the 
major limitation in the field lies in the scarcity of chemical tools currently at our disposal. All the 
ferroptotic discoveries described above were conducted in a limited set of cell lines (i.e. HT-
1080, BJ-RAS mutated engineered cell systems). Selection of such cells proved problematic; for 
example, when attempting to link RAS mutation to compound activity in a panel of diverse 
cancer cell lines.12 Erastin and RSL3 showed minimal to no activity. These data challenged the 
relevance of RAS-mutational status and the selective synthetic lethal ability of these compounds 
in cancer treatment. Despite this glaring lack of mechanistic understanding, erastin and RSL3 
remain the two gold-standard small molecules for studying ferroptosis. 
Furthermore, the bioactivity of these reported probes is linked to specific cell lines and is 
limited to HT-1080 or BJeLR xenograft studies in vivo12. For example, erastin is not active in 
breast cancer (4T1), lung cancer (A549) or colon cancer (HCT 116) cell lines as we will explore 
in chapter 2 of this thesis. Due to its low water-solubility, erastin is not used in animal models; 
piperazine analogue is used instead but a comprehensive ferroptotic data profile is missing for 
this analogue.12 While RSL3 displays activity, it suffers from lack of quantitative cell death, slow 
reactivity in cells and limited cell line activity in mice12.  As a practical consideration, fast-
acting, reliable, and bioavailable compounds are critical when performing biological experiments 
and animal work. However, the reported ferroptotic inducers are unable to do so, demonstrating 
the need for development of new chemical probes with broad bioactivity to further investigate 
ferroptosis and its underlying mechanisms not only in cells but also in vivo. 
1.4 Ferroptosis and oxytosis 
A closely related mode of cell death to ferroptosis is oxytosis, which was reported in 2001. 
Treatment of neuroblastoma cells with glutamate and glutamate analogues, resulted in ROS 
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Figure 1.7. Common pathways in oxytosis and ferroptosis. Image is adapted with 
permission from Lewerenz and coworkers.5  
generation and glutathione depletion followed by a lethal calcium influx.9 The first two events 
are core ferroptotic features and highlight the parallel between these two cell death modalities 
and their dependency on system XC
-. This system transports extracellular cysteine inside cells for 
production of glutathione in a 1:1 exchange rate with intracellular glutamate (Fig. 1.7).5  
Indeed, high extracellular levels of glutamate behave similarly to treatment with the 
ferroptosis-inducing compound erastin; they both cause inhibition of system XC
-, leading to 
depletion of glutathione and inactivation of GPX4. This process results in accumulation of lipid 
hydroperoxides, massive accumulation of reactive oxygen species (ROS), mitochondrial ROS, 
and other dysfunctions in cells.46 Despite the similarities in the initiation phase (system XC
- 
inhibition), the termination phase of these two forms of cell death is drastically different. 
Oxidative glutamate toxicity (oxytosis) requires additional downstream events that involve 
apoptotic features and are dependent on calcium intake instead of iron, especially in neuronal 
cells; meanwhile, calcium is not needed in ferroptosis though its role is not well understood.9,36,47 
A high degree of overlap of these cell death mechanisms is observed in other cell types.3 
However, more functional studies are needed to further substantiate the distinction between these 
two cell death mechanisms.  
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1.5 Therapeutic targeting of ferroptosis 
The continual accumulation of compelling evidence highlights ferroptosis as a potential 
novel and efficient inducer of cell death for anticancer treatment that can be achieved via two 
strategies: 1) identification of small molecule inhibitors with broad anticancer activity 2) 
inhibition of key molecular targets in multiple pathways that activate ferroptosis. Most of the 
ferroptotic-inducers were discovered in synthetic lethal screens with selectivity towards RAS 
mutated engineered cells. Nonetheless, subjecting 117 cell lines isolated from diverse tissues 
(leukemia, lung, colon, CNS, melanoma, ovarian, kidney, and breast) and the NCI-60 panel to 
erastin and RSL3 revealed no selective preference of such compounds for RAS mutated versus 
RAS wild type cancer cells.12 This study unveiled that diffuse, large B cell lymphomas and renal 
cell carcinomas appear to be particularly sensitive to ferroptosis. Notably, sorafenib, an FDA-
approved multikinase inhibitor for renal carcinomas, was found to display a ferroptotic profile 
due to inhibition of system XC
-.30 Tumors resistant to sorafenib contain high levels of the 
negative regulators of ferroptosis (Nrf2 and MT-1G) and can be re-sensitized to the this kinase 
inhibitor upon pharmacological or genetic inhibition of these regulators in vitro and in xenograft 
mouse models.32,48  
Furthermore, targeting of tumors dependent on system XC
- (ideally in systems with inactive 
transsulfuration pathways) could be a viable anticancer approach to promote cancer cell death. 
Triple negative breast cancers (TNBC) are an excellent model, as they survive on the interaction 
of this cysteine/glutamate transporter with MUC1-C transmembrane oncoprotein and directly 
respond to sulfasalazine or erastin treatment displaying a ferroptotic phenotype.49 Combination 
of class I inhibitors, especially the FDA-approved examples (sorafenib and sulfalazine) with 
chemotherapeutics currently used for treatment of TNBC is an underexplored area of research. A 
15 
 
phase II clinical study evaluated sorfenib with taxane/anthracycline chemotherapeutics in HER2 
negative patients and reported no drug–drug interactions for the sorafenib/epirubicin 
combination.50 In another trial, HER2 negative trial sorafenib/capecitabine combination resulted 
in significant progression free survival but had to be discontinued due to compound toxicity.51 
These trials were not selective for TNBC patients per se, but do offer insights into the potential 
of developing new combinations specifically for TNBC patients, based on our sorafenib-
ferroptosis knowledge. 
In addition, expression of the system XC
- is correlated with the malignancy grade of brain 
tumors.52,53 Savaskan and coworkers demonstrated that pharmacological and genetic inhibition 
of this system causes ferroptosis and disrupts the neurodegenerative and toxic environment of 
gliomas.54,55 Combination of temolozomide (TMZ) with erastin (not sorafenib) potentiates the 
sensitivity of gliomas to TMZ,  prompting a new multitoxic approach in treatment of brain 
tumors. Given the drastically low patient response rate to TMZ treatment,56 and lack of other 
treatment options for brain cancers,57 combination of TMZ with reliable ferroptotic compounds 
could be useful, of course pending sufficient blood-brain barrier (BBB) penetrance for these 
compounds. Currently, there is no data on the ability of ferroptotic compounds to cross the BBB, 
so future efforts will need to explore this area in the context of assessing combination therapy in 
brain cancers. As described earlier, glutaminolysis is another crucial system in ferroptosis that 
can be exploited as an anticancer strategy. The combination of ferroptosis dependence on this 
vital metabolic process for cancer cell proliferation and targeting of  glutaminolysis molecular 
components for inhibition could serve as another potential therapeutic avenue.54 
A limited number of studies have investigated the potential link of ferroptosis to pathological 
cell death, particularly in neurodegenerative disease models. Oxidative damage, lipid oxidation, 
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iron accumulation, dysregulation of GSH and decrease GPX activity are the common features 
found in brains of patients with Parkinson’s (PD)58-60, Alzheimer’s (AD)61, Hungtington’s 
(HD)62-64, periventricular leukomalacia (cerebral white matter injury)65,66, and ischemic stroke67-
69, thus connecting ferroptosis to brain disease. Iron chelation, administration of vitamin E or 
ferrostatin-1/liproxstatin-1 was shown to reduce the neurodegeneration levels in the mouse 
models of PD70,71, AD72, and HD18,64. Other reports have demonstrated that ferroptosis is 
involved in tissue/organ injury due to ischemia/reperfusion, and inhibition of ferroptosis is 
effective in treatment of organ damage.73,74  
These reports provide evidence for use and exploration of ferroptosis-inducing compounds in 
multiple disease areas outside the realm of oncology. This is highly attractive as it creates new 
frontiers for investigation of ferroptosis as an important biological process in a broad range of 
disease areas, meaning it is not just another form of non-apoptotic cell death. Induction of 
ferroptosis can be a powerful anticancer strategy and it appears to be a key process in 
neurological disorders. Therefore, compounds that reliably trigger ferroptosis in various systems 
(cell lines and/or animal models) are of paramount importance, particularly considering our 
current array of imperfect ferroptotic tool compounds. 
1.6 Cell death and immunity 
Historically, apoptosis has been the most studied form of regulated cell death and is thought 
to be tolerogenic since it is the main method of clearance of abnormal cells via phagocytosis 
(also known as efferocytosis), thus preventing inflammation.75-77 However, recent studies have 
provided evidence of other regulated non-apoptotic forms of cell death with well-defined 
initiation and execution mechanisms. Such modes of cell death can release damage-associated 
molecular patterns (DAMPs), triggering activation of the neighboring macrophages and dendritic 
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cells via Toll-Like-Receptor signaling and other signaling pathways.78 This activation involves 
expression of tumor infiltrating lymphocytes and/or initiation of an adaptive immune response, 
both of which are highly attractive strategies in the clinic.77  
Given the scientific community’s appreciation of the role of the immune system in cancer 
and the potential of immunology in the clinic, there is an increased interest in methods that will 
activate the immune system to elicit an immune response. The most developed approach thus far, 
is immunotherapy, which relies on biologics such as antibodies, bispecific T-cell engagers, 
antibody drug conjugates (ADCs), and vaccines, to activate the immune system to kill cancer 
cells. A different strategy is to obliterate these malignant cells via small molecules that induce 
non-apoptotic cell death and can thus release DAMPS to signal an immune response.  
Conventional chemotherapeutics (doxorubicin, taxanes, Pt-based compounds, methotrexate, 
and gemcitabine, to name a few) have been shown to display immunological effects in a dose-
dependent manner, as discovered through metronomic chemotherapy—chronic administration of 
chemotherapy at low, minimally toxic doses, with no prolonged drug-free periods—yet their 
primary mechanism of action is some form of apoptosis.79,80 Additionally, numerous efforts have 
focused on developing small molecules with immunostimulatory effects, but most of these are in 
the early stages of development (Table 1.2).2 Therefore, identification of non-apoptotic 
compounds that can directly elicit an immune response or enhance the effect of  immunotherapy 
are highly desirable in the clinic. In the later chapters, we will demonstrate how a small molecule 
discovered in our laboratory can potentially play a part in developing this frontier. 
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Table 1.2. Categories of small molecule compounds with immunomodulatory functions in solid tumors. 
Abbreviations: DC: dendritic cell, DNMT: DNA methyltransferase, HDAC: histone deacetylase complex. 
IDO: indoleamine-2, 3-dioxygenase, RORɣt: Retinoic acid receptor-related orphan nuclear receptor gamma, 





1.7 Conclusions and outlook 
In this chapter, I have surveyed non-apoptotic forms of cell death with a focus on ferroptosis, 
a new mode of regulated cell death. An overview of all the pathways currently involved in 
ferroptosis as well as its hallmarks were presented to help the reader better understand where 
ferroptosis stands in the landscape of other RCDs. Despite its partial overlap with oxytosis, 
ferroptosis is morphologically, biochemically, and genetically different from other known cell 
death modalities, and thus is an important biological process for future study and applications. 
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Multiple groups have directed their attention towards ferroptosis, generating several 
ferroptosis-activators and inhibitors. However, activity of these compounds is limited to specific 
cell lines and currently target one of two ferroptotic pathways: depletion of glutathione or 
inactivation of GPX4. Discovery of tool compounds that would further elucidate the molecular 
mechanism of ferroptosis, identify biomarkers of ferroptosis in vivo, and have broad activity is 
of paramount importance. Furthermore, ferroptosis-inducing compounds have the potential to 
activate the immune system via the release of DAMP signals to combat cancer; however, more 
in-depth studies are needed to prove or disprove this hypothesis. 
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Chapter 2: Discovery of Ferroptocide 
2.1 Phenotypic screening 
Phenotypic screening, also known as forward chemical genetics, is the historical mode of 
screening in drug discovery.1-3 It consists of subjecting a library of compounds to a target 
agnostic screen and monitoring disease-linked phenotypes. The compounds that elicit the desired 
phenotype are considered small molecule hits. Conducting hit-to-lead studies is a significant 
challenge, however, as the target of each hit is unknown. The rate limiting step thus becomes 
target identification and elucidation of the mode of action of the compound of interest. Recent 
advances in chemical biology techniques have enabled rapid target discovery and shortened this 
timeline to months instead of years, but the intricacies involved in identifying the underlying 
biology still require significant technical expertise.4 
Some of the inherent advantages of phenotypic screening include: screening in 
physiologically relevant contexts (minimally cell-based or animal-based models), uncovering 
new targets or molecular mechanisms of actions (MMOA), and identifying cell permeable hit 
compounds.3,5 Most of the commonly prescribed drugs in the clinic (anthracyclines [i.e. 
doxorubicin], paclitaxel, vinca alkaloids, etc.) were discovered through phenotypic screening 
efforts conducted in animal models of leukemia and lymphomas in the 1960s6, which speaks to 
the utility and value of phenotypically discovered drugs.  Furthermore, a detailed analysis by 
Swinney and Anthony of all 75 first-in-class FDA approved drugs from 1999–2008 revealed that 
28 of these drugs were discovered through phenotypic screening approaches, while 17 came 
from target-based approaches (Fig. 2.1).1 At the time, this study questioned the industry’s heavy 
focus and investment on target-based technologies since the mid-1980s. Sequencing of the 
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human genome, advancements in high throughput screening technologies and modern biological 
techniques, coupled to progress in combinatorial and parallel chemistry had inspired a target and 
hypothesis-based approach to drug discovery, and yet the industry was facing the challenge of 
low productivity in research and 
development (R&D). This study shed 
light into the problems observed in 
industry. An updated survey of first-in-
class drugs approved from 1999–2013 
indicated that from 113 first-in-class 
drugs, 78 were developed from target-
based screens (45 small molecules and 33 
biologics) and 33 from system-based 
approaches in direct contrast to the initial 
report.7 The reasons for the apparent 
discrepancy were attributed to the additional 5-year period of the second analysis and the 
semantic distinctions in the definition of phenotypic screen vs chemocentric and/or active 
pharmacophore screens.  
The high attrition rates of compounds in the clinic, especially due to lack of efficacy 
attributed to the reductionist approach to disease biology (focusing on insufficiently validated 
targets and lacking consideration for target engagement in vivo)8 have recently instigated a 
“resurrection” of phenotypic screens in oncology R&D programs throughout the US.9-11 The 
modern phenotypic assays aim to incorporate clinically relevant biological systems with a clear 
Figure 2.1. Distribution of first in class drugs approved 
from 1999–2008. Phenotypic screens generated more first 
in class drugs than target-based screens. Image is 
reproduced with permission from Nature1. 
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link to disease such as induced pluripotent stem cells (iPSC), patient-derived primary cells, 3D 
systems, and cell co-culturing models.3,9  
Other important considerations are the assay stimuli and readouts. Ideally, the readout is 
a translational biomarker close to a clinical endpoint such as muscle contraction, contraction of 
heart tissues for beta blocker development, patient-derived airway epithelial cells in the case of 
cystic fibrosis coupled to measurement of channel activity and the airway surface liquid release, 
etc.11 The future of phenotypic assays lies in screening libraries of compounds with unique 
physiochemical properties (different from the current commercial screening libraries) in a 
clinically relevant endpoint assay using patient-derived models.  
2.2 Library considerations: CtD library 
Of critical importance when conducting a phenotypic screen is the compound collection. 
Commercially available libraries (Chembridge, Microformat, PNAS CC) are mainly comprised 
of flat, aromatic compounds possessing a low number of stereogenic centers, sp3-hybridized 
carbons (Fsp3), and ring complexity (Fig. 2.2).
1,12 Assessment of the complexity of approved 
oncology drugs by these three metrics indicates that FDA-approved anticancer drugs are more 
complex than compounds in commercial libraries. Therefore, there is a critical need for complex 
and diverse small molecules. The Hergenrother lab’s approach to addressing this challenge is 
coined complexity-to-diversity (CtD), where complex and readily available natural products are 
subjected to short (≤ 7) synthetic steps to arrive at complex and diverse scaffolds (Fig. 2.3). 
Evaluation of the complexity of the CtD library demonstrates that the resultant compounds have 
a high number of chiral centers, high Fsp3, and enhanced ring complexity similar to FDA-




Figure 2.2. Comparison of complexity metrics (chiral centers, Fsp3, and ring complexity) of 
pleuromutilin compounds with various small molecule libraries. Violin plots shown, where width 




  Currently, there are >600 compounds synthesized via the CtD strategy applied to 
adrenosterone,13 gibberellic acid,13 quinine,13,14 abietic acid,15 sinomenine,16  pleuromutilin, and 
lycorine17 in our lab. Additionally, various academic labs have adopted and applied this approach 
to several natural products such as yohimbine,18 haemanthabine,19 nitrogenous steroids of 
dutasteride and abiraterone acetate,20 ilimaquinone,21 and others.  The resulting collections of 
complex compounds have been used to discover small molecules with anticancer and 
antimicrobial activities, autophagy inhibitors,18,22,23 and to identify predictive guidelines for 
broad-spectrum antibiotic discovery.24   We hypothesized that subjecting our in-house CtD 
library to a cytotoxicity phenotypic screen would enable discovery of compounds with new 
MMOA. 
 
Figure 2.3. Following the Complexity-to-Diversity strategy six natural product are 
transformed in short synthetic sequences to comprised of a 341member library. 
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 Name Percent Dead IC50 
(µM) 
 
HCT 116: 84.8 % >100
KCM VI-118 ES-2: 65.4% >100  
Mia PaCa-2: 69.4% >100 
    
HCT 116: N/A - 
RJR-III-014Y ES-2: N/A -  
Mia PaCa-2: 50.8 % 16.7 
    
HCT 116: 68.5 % >100 
MFR-I-93 ES-2: 71% >100  
Mia PaCa-2: 71% >100    
 
HCT 116: 68.5 % > 16.6 
RH2-4-87B-2 ES-2: 71% 21.5  
Mia PaCa-2: 71% 5.1 ± 2.2    
 
HCT 116: 62.9 % 10.6 
HR-05-225 ES-2: 51% >100  
Mia PaCa-2: 60.9% >100    
 
HCT 116: 47.2 % 6.3 ± 2.5 
RH2-5-85-2 ES-2: 73.7 % 2.0 ± 0.4  
Mia PaCa-2: 54 % 5.0 ± 2.6    
 
HCT 116: 53% >100 
MFR II-262 ES-2: N/A -  
Mia PaCa-2: N/A -    
 
HCT 116: N/A - 
RH2-1-213-D ES-2: 65.8 % >100  
Mia PaCa-2: N/A -    
 
HCT 116: N/A - 
RJR-II-136 ES-2: 65.8 % >100  
Mia PaCa-2: N/A -    
 
HCT 116: N/A 13.4 ± 
7.8  RH2-5-93-1 ES-2: 49.5 % 4.8 ± 3.3  
Mia PaCa-2: N/A 18.2 
 Mia PaCa-2: N/A 9.1 ± 3.4 
P4 HCT 116: 63.4 % 19.7 ± 
2.5 
 
ES-2: 53.2 % 6.7 ± 0.4 
Table 2.1. Hit compounds identified through an anticancer phenotypic screen and their respective IC50 values. 
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2.3 Anticancer phenotypic screening of the CtD library 
Compounds from CtD were evaluated in whole-cell assays for their ability to rapidly kill 
cancer cell lines in a primary screen against the ES-2 (ovarian cancer), HCT 116 (colon cancer), 
and Mia PaCa2 (pancreatic cancer) cell lines. Such cell lines were selected as representatives of 
challenging-to-treat cancers. All compounds were assessed at 12 µM, with cell viability 
determined using the Alamar Blue viability assay. Compounds that elicited at least 50% cell 
death were considered hit compounds and were then evaluated through full dose-response curves 
(Table 2.1). From these assessments, four compounds were identified as having promising 
activity, with rapid induction of cell death (characterized further below). Three of the most active 
compounds were derived from the pleuromutilin (P) natural product and thus were prioritized for 
further investigation.  
Pleuromutilin is a diterpenoid that was first isolated from basidiomycetes in 1951 by 
Kavanagh and co-workers.25 The natural product P is found in several species of fungi and is a 
potent inhibitor of the bacterial 50S ribosome.26-28 P is composed of 5-, 6-, and 8-membered 
rings and contains eight contiguous stereogenic centers. Several semisynthetic derivatives of P 
are used to treat Gram-positive pathogens in humans (retapamulin) and in veterinary medicine 
(tiamulin, valnemulin),26,29 and recently epi-mutilin derivatives have been developed as 
antibiotics with activity against some Gram-negative bacteria.30-33 Investigation of the 
antibacterial activity of P and its derivatives has inspired several endeavors in its total 
synthesis31,32,34-36 that, combined with previous work on structure elucidation37,38 and structure–
activity relationship studies (SAR),39-41 provide a wealth of synthetic information about the 
chemical reactivity of the P ring system. Such data was critical in constructing a small set of 
highly complex and structurally diverse compounds using P as a starting material (Fig. 2.2). 
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2.4 Structure–activity relationship studies 
2.4.1 SAR studies of 85-2 hit compound 
 Upon dose-response validation of hit compounds as shown in Table 2.1, two compounds 
were prioritized for additional SAR studies (85-2 and P4). Compound 85-2 is certainly a non-
conventional lead compound due to the TBS-protecting functional group. Uses of silicon as a 
carbon isostere is one approach of discovering new drug-like entities with favorable biological 
properties in medicinal chemistry.42  Literature reports indicate that silicon can be used as a 
carbon bioisostere  (as in silaproline),43 and similar silicon-containing compounds can display 
activity against influenza proton channels and CNS receptors (azasilines),43 inhibit p38 MAP 
kinase activity (BIRB-796 Si-analogue),44 function as opioid receptor agonists (sila-
loperamide),45 and display anticancer activity (5-tert-butyl-2-furylmethylidene-aniline silicon 
analogues, 3i)46 as shown in Figure 2.4. Head-to-head comparisons of biological properties of 
silicon and carbon analogues demonstrate that silicon does not pose metabolic, efflux, or drug–
drug interaction liabilities and can potentially improve oral bioavailability as shown for selective 
azasilanes.43  
 




Despite the fact that 85-2 possesses a TBS protecting group and is not a silicon analogue, 
this scaffold was advanced for minimal SAR studies as shown in Fig 1.5. Substitution of the α-
choro ester with an acetate (5-259) or furoic ester (6-69) results in loss of anticancer activity, 
while insertion of an azido group (1-47) improves activity in HCT 116 colon cancer cells and 
retains activity in an ovarian cancer cell line (ES-2). Modification of the secondary alcohol (295-
1) is not tolerated while [4+2] cycloaddition of the diene resulted in the most active derivative of 
the series (5-271). To investigate the importance of the TBS group, TES derivatives (6-45, 6-
93C, 6-87) were synthesized and tested for biological activity. Dose-response studies revealed 
that TES derivatives had diminished anticancer activity compared to their TBS- analogues, 
suggesting a potential interference in target engagement due to the bulkiness of the ethyl groups. 
 
Figure 2.5. SAR studies of 85-2 scaffold discovered through an anticancer phenotypic screen of CtD library. 
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2.4.2 SAR studies of P4 hit compound 
Another key compound discovered through the anticancer phenotypic screening effort 
was compound P4. Given the interest in P-derived compounds for antibacterial treatment, the 
discovery of P4’s anticancer activity warranted further pursuit. P4 was a favorable hit compound 
due to the many functional group handles present in the molecule (color-coded in Fig. 2.6). In 
collaboration with Dr. Rob Hicklin (all SAR compounds) and undergraduate Mike Vinyard (for 
the azido derivatives), a series of compounds were synthesized and tested for activity (Fig. 2.6).  
Methylation (6-147) and acetylation (5-287) of the secondary alcohol is moderately 
tolerated while modification of the diene (5-267) is highly favorable. The α-chloro ester moiety 
is deemed to be a key handle for activity. Indeed, removal of the α-chloro ester (5-227) as well as 
substitution with an acetate-, fluoro-, furan-, azido group results in loss of bioactivity 
(compounds 5-227, 5-261, 6-197, 6-89, 6-143 respectively). The most active compound from 
both SAR campaigns was 5-267, hereafter referred to as ferroptocide. This scaffold was 




Figure 2.6. Investigating the functional groups need for activity of P4 hit compound. 
2.4.3 SAR studies of lead compound ferroptocide 
Ferroptocide is more potent than hit compound P4, with an IC50 = 1.6 µM against ES-2 
cells. Further modification of the secondary alcohol and the α-chloro ester of ferroptocide 
unveiled structural features important for activity. While methylation and acetylation of the 
secondary alcohol of ferroptocide (P19 and P20, respectively) did not change the activity (Fig. 
2.7), replacement of the α-chloro ester with an acetate group (P21) eliminated activity.  To 
investigate other electrophilic groups the fluoro- (P22) and iodo- (P23) compounds were 
synthesized.  While P22 had greatly diminished anticancer activity, the iodo analogue (P23) 
showed greater potency in cells at the expense of biological selectivity (Fig. 2.8).  Additional 
compounds with poor leaving groups such as α-acetate ester (P24), α,α dichloro ester (P25), 
furoic ester (P26), and azido ester (6-127) exhibited no anticancer activity (Fig. 2.7). Another 
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highly used group in medicinal chemistry and present in many approved drugs is the acrylate 
functional group. Synthesis of the acrylate analogue (7-103) did not improve nor diminished 
bioactivity. Ferroptocide remained the most active derivative after this extensive SAR analysis.   
 










2.4.4 Synthesis and evaluation of tool compounds 
Additional synthesis and evaluation revealed that the two bridgehead nitrogens in the 
urazole ring of ferroptocide could be removed (P28, Fig. 2.9) with minimal loss in activity.  
This discovery allowed for the construction of the alkyne tool compound P29 (Fig. 2.9), which 
was further modified via a 1,3-dipolar cycloaddition resulting in fluorescent compound P30. 
Both P29 and P30 retained anticancer activity similar to ferroptocide (Fig. 2.9), and P30 was 
used as a probe compound to explore subcellular localization. As shown by confocal 
microscopy, P30 localizes to the cytoplasm in ES-2 cells. Additionally, a biotin analogue of 
Figure 2.9. Synthesis of tool compounds and their biological activity. P30 compound localizes 
in the cytoplasm of ES-2 cells after 30 min treatment. Hoechst dye is used to stain the nucleus.   
Figure 2.8. (A) Promiscuous bioactivity of the Iodo fluorescent analogue (P31) upon 30 min 
dose-dependent treatment with compound. (B) Coomassie stain of gel demonstrates equal loading.  
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ferroptocide (7-217) was synthesized but displayed diminished bioactivity potentially due to 
lack of cell permeability as observed from the large molecular weight of such scaffold. 
2.4.5 Investigation of other α-chloro esters 
α-Chlorocarbonyl electrophiles are expected to be reactive towards nucleophilic 
substrates due to their high reactivity.47 Such scaffolds including chloroacetamides, chloromethyl 
ketones, p-chloronitrobenze electrophiles and others, tend to react with cysteine thiols in cells 
due to the polarizability and electron-rich nature of sulfur. The main cysteine-rich endogenous 
nucleophiles include glutathione (the most abundant nucleophile in cells), gamma glutamyl 
cysteine (precursor of glutathione), and la antigen (RNA chaperone that facilitates correct 
processing and maturation of RNA polymerase III transcript) among others. In addition, residues 
such as serine, lysine, tyrosine, threonine, aspartate, and glutamate have the potential to be 
nucleophilic and react with these electrophilic compounds depending on the protein 
environment.  
Figure 2.10. A subset of FDA approved drugs containing carbonyl electrophiles 
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A detailed report by Klein and co-workers48 demonstrated via an extensive study of the 
biochemical reactivity of 72 compounds containing diverse electrophilic groups towards 11 
pharmacologically relevant targets, that chlorocarbonyl  electrophiles exhibit surprisingly low 
off-target reactivity and minimal activity towards glutathione (GSH, kGSH∼0.1 l·mol−1·s−1). The 
authors concluded that these functional groups can be suitable warheads for designing targeted 
covalent inhibitors. Indeed, many covalent drugs (Fig. 2.10) that contain electrophiles such as 
Figure 2.11. Fluorescent signal of P30 is competed away upon pre-treatment with ferroptocide but not with the 
other three α-chloro esters. ES-2 cells were pre-treated at 3x IC50 value for 30 min followed by treatment with P30 
(5 µM). Nucleus was stained with Hoechst. 
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ibrutinib, finasteride, rivastigmine, and bortezomib are shown to be highly specific towards 
Bruton’s kinase, 5α reductase, cholinesterase, and the proteasome, respectively.49,50,51 
Importantly, installation of an α-chloro ester on pleuromutilin itself (P27), and other 
scaffolds such as lovastatin (L1), and quinine (QQ1), did not result in notable cell death or 
compete with P30 in a confocal microscopy experiment as shown in Figure 2.11, demonstrating 
that the anticancer activity of ferroptocide is not attributed solely to the presence of an 
electrophilic functional group.  
2.4.6 Assessing ferroptocide reactivity with glutathione 
To further probe the selectivity of ferroptocide, compound reactivity with glutathione 
(GSH) was monitored at therapeutically relevant levels (5 mM). Such reactivity is a key feature 
of the pan-assay interference chemotypes.47 Upon 2 hr treatment, ferroptocide did not display 
notable reactivity towards GSH even at 50 fold excess (Fig. 2.12.A). Time-course monitoring of 
GSH-ferroptocide adduct formation in a separate experiment, revealed that ferroptocide reacts 
relatively slow with glutathione over the course of 24 hr (30% remaining compound after 24 hr 
as shown in Table 2.2.). The highly electrophilic iodo analogue (P23) reacted immediately, 
while the less electrophilic dichloro analogue (P25) was non-reactive (Fig. 2.12. B, C 
respectively). These findings are consistent with the suspected SN2-type reactivity as showcased 
during the SAR studies. Due to favorable selectivity and reactivity results, ferroptocide was 
prioritized for mode of action studies. 
 
































Figure 2.12. A–C. Monitoring the reactivity of 100 µM ferroptocide, P23, and P25 respectively with 5 
mM GSH at 37°C in PBS using an LC/MS-based method. Ferroptocide reacted at a slow rate, P23 reacted 




2.5 Assessing hemolysis of compounds of interests  
Ability of compounds to induce red blood cell lysing, also known as hemolysis, is a 
major safety hurdle for translation of compounds into the clinic as it is suggestive of broad 
cytotoxicity. Therefore, early in the discovery process, potential drug leads are rigorously 
assessed for their hemolytic ability to avoid investment of time and resources on risky 
compounds. To monitor hemolysis of compounds of interest, P4 and ferroptocide were assessed 
in an in vitro assay using freshly purchased human blood. Both compounds did not induce lysing 
of red blood cells at 333 µM, as shown in Fig. 2.13 suggesting therapeutic relevance and lack of 
broad toxicity. Further investigation of toxicity in animals (e.g. mice) must be performed to 







Figure 2.13. Assessment of the hemolytic ability of P4 and ferroptocide at 333 µM. These compounds are 
non-hemolytic suggesting lack of broad toxicity. DMSO in water was used as a positive control and DMSO 
in red blood cell buffer was a negative control. 
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2.6 Compound activity in a panel of cell lines 
Immortalized mammalian cancer cells are the workhorse of cancer research, and yet they 
are often poor surrogate models of cancer. They are susceptible to genetic variations (e.g. 
somatic mutations, chromosomal aberrations, etc.) and are neither clonal nor genetically stable.52 
A recent study investigated different types of commonly used breast cancer cells, MCF7, from 
27 different sources and upon comprehensive sequencing identified rapid genetic discrepancies 
due to positive clonal selection sensitive to cell culture conditions.52 Primary cancer cells on the 
other side are a more relevant testing model, but they are difficult to access as Institutional 
Review Board (IRB) approval and patient consent is needed; additionally, they are challenging to 
isolate and susceptible to contamination. A successful collaboration with oncologists at Carle 
Foundation hospital enabled access to multiple metastatic cancer patient biopsies and 
establishment of primary cancer cell lines temporarily.  
Figure 2.14. Ferroptocide displays broad activity (µM) in a 72 hr cell viability assay in immortalized cancer cells 
and in primary cells isolated from metastatic cancer patients. PPC: primary peritoneal carcinomas. Data represent 
the mean ± s.e.m., n≥3. 
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Evaluation of ferroptocide in a panel of cancer cell lines and primary cancer cells 
revealed broad activity across different types of cancer with an IC50 range of 1.6–24 µM for 
immortalized cancer cell lines and 1–5 µM for primary cancer cells obtained from metastatic 
patients, as shown in Figure 2.14. Interestingly, ferroptocide was more active in primary cancer 
cells than in immortalized cell lines supporting the therapeutic relevance of this lead compound. 
Such results inspired comparison studies of ferroptocide with FDA-approved drugs (5-FU, 
cisplatin, etoposide) and clinical drug candidate (PAC-1), which demonstrated a more active 
anticancer profile for ferroptocide than the other drugs in a 72 hr assay (Fig. 2.15). 
 
2.7 Mode of action studies 
2.7.1 Ferroptocide speed of cell death 
In order to gain insights into the mode of anticancer activity, the speed of cell death of 
ferroptocide was compared to other approved chemotherapeutics and tool compounds with 
well-defined mechanisms including: procaspase-3 activators (PAC-1, 1541B),53 nucleoside 
analogues (gemcitabine, 5-FU), DNA alkylators (MNNG, mitomycin C), topoisomerase 
inhibitors (etoposide, camptothecin, cycloheximide), ROS inducing agents (anitimycin A, IB-
Figure 2.15. Effect of ferroptocide and approved 
and experimental chemotherapeutics (5-FU, 
Cisplatin, Etoposide, PAC-1) in primary patient-
derived cells in a 72 hr cell viability Alamar Blue 
assay. Cells tested are those shown in Fig. 2.14.  
Data represent the mean ± s.e.m., n≥3. 




















DNQ,54 rotenone), broad-spectrum kinase inhibitor (staurosporine), microtubule stabilizer 
(taxol), proteasome inhibitor (bortezomib), and a rapid apoptosis-inducing agent (Raptinal).55 
Cell death induced by ferroptocide was rapid in multiple cell lines derived from diverse cancer 
types, with a time to 50% cell death of 1 hour in ES-2 cells, (Fig. 2.16 A), 1.5 hr in Mia PaCa-2 
(Fig. 2.14B), 7 hr in HCT 116 (Fig. 2.16C), and 7 hr in 4T1 (Fig. 2.16D). As the speed of cell 
death induced by ferroptocide was faster than the most rapid proapoptotic agent known 




Figure. 2.16. (A) Speed of death of cells treated with 
ferroptocide versus 16 other anticancer compounds in 
ES-2 cells (all tested at 10 µM). Cell viability was 
assessed by AV/PI analysis. Data is representative of 
three biological replicates. (B–D) Speed of cell death of 
ferroptocide (10 µM) and other tool compounds (STS, 
MNNG) in Mia PaCa-2, HCT 116 cells and 4T1. 
Ferroptocide causes 50% cell death in 2 hr, 7 hr, and 7 hr 
in each cell line, respectively. Cell viability was 
determined via AV/PI staining. Error is standard error of 
the mean, n≥3. 
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2.7.2 Ferroptocide is non-apoptotic 
To assess for early events of 
apoptosis, exposure of phosphatidylserine 
(PS) on the outer leaflet of the plasma 
membrane is monitored via flow cytometry 
using FITC-Annexin V and propidium 
iodide (PI) staining. Apoptotic cells are 
those that stain positive for FITC-Annexin V 
and negative for propidium iodide. Time 
course analysis of cells treated with 
ferroptocide followed by Annexin V/PI 
staining suggested a non-apoptotic mode of 
cell death as observed in Figure 2.17. The 
live cell population (FITC-Annexin V 
negative, PI-negative) migrates diagonally across the four quadrants instead of through the 
canonical apoptotic pathway. To further support these findings, protection experiments with the 
pan-caspase inhibitor Q-VD-OPh were performed.  As shown in Figure 2.18 A,B  Q-VD-OPh 
protects ES-2 and HCT 116 cells against the effect of the positive control Raptinal but has no 
effect against ferroptocide-induced cell death.  
Additionally, cleavage of PARP-1 by caspase-3 is a common feature of apoptotic 
compounds in cells. Such marker was seen in Raptinal-treated ES-2 and HCT 116 cells but not in 
ferroptocide-treated cells as displayed by western blot analysis in Figure 2.18 C and D, 
respectively, suggesting non-apoptotic activity for our lead compound.  
Figure 2.17. Time-course analysis of ES-2 cell viability 
upon treatment with ferroptocide (10 µM) indicates a 
non-apoptotic mode of cell death. AV/PI graphs are 
representative of three biological replicates. 
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Figure 2.18. (A–B) Effect of pre-treatment with Q-VD-OPh (25 µM) for 2 hr followed by dose-response treatment 
with ferroptocide or positive control Raptinal (5 or 10 µM) for 13 hr in ES-2 and HCT 116 cells. Data are plotted as 
the mean ± s.e.m., n=3 biological replicates. *** 0.0001 ≤ p < 0.001, n.s. not significant. (C–D) Immunoblots of ES-2 
and HCT 116 cells indicate no PARP-1 cleavage after 1 hr and 7 hr treatment (respectively) with ferroptocide (P18). 






As further confirmation, cell 
morphological changes induced by 
ferroptocide and the positive control 
staurosporine (STS) were examined 
using transmission electron microscopy 
(TEM). Cells treated with ferroptocide 
exhibit none of the characteristics of 
apoptosis such as membrane blebbing, 
chromatin condensation, nuclear 
fragmentation, reduction of cellular 
volume, or rounding of the cell (Fig. 
2.19).56 Taken together, these data indicate that ferroptocide induces rapid, non-apoptotic cell 
death. As compounds with such a mode of cell death can have unique properties and advantages 
in vivo,57-59 further elucidation of the mechanism of cell death of ferroptocide was of interest. 
2.7.3 Ferroptocide co-localizes to mitochondria 
The TEM images (Fig. 2.19) reveal 
mitochondrial swelling as early as 30 minutes after 
ferroptocide treatment suggesting mitochondrial 
dysfunction due to compound treatment. To investigate 
this hypothesis, subsequent confocal microscopy 
Figure 2.19. Transmission electron micrographs of ES-2 cells 
treated with DMSO (left), ferroptocide (10 µM, center) or 
staurosporine (STS, 10 µM, right) for 30 min. The images show 
lack of apoptotic morphological features and swelling of 
mitochondria upon ferroptocide treatment (red arrows) versus 
controls. TEM data are representative images. 
Figure 2.20. Co-localization analysis of ferroptocide with 
mitochondria. ES-2 cells were stained with MitoTracker Red (100 
nM) followed by 30 min treatment with fluorescent analogue P30 
(10 µM). Nucleus was stained with Hoechst. Yellow dots indicate 
P30 (green) on the mitochondria (red) in merged images. 
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experiments were conducted. These studies supported the prior TEM findings as the fluorescent 
analogue P30 was found to co-localize with the Mitotracker dye in cells (Fig. 2.20). Localization 
of compounds to certain organelles can be informative when determining the mechanism of a 
compound. These data indicate a mitochondrial-based activity of ferroptocide directing our 
attention towards mitochondria for more in depth-mechanistic studies. 
2.7.4 Ferroptocide induces cellular ROS formation 
Mitochondria are an important source of reactive oxygen species (ROS), which can 
contribute to oxidative damage to mitochondrial proteins, membranes, DNA and redox signaling 
in mammalian cells.60 Production of ROS in mitochondria can result in impairment of their 
synthesis of ATP and various metabolic processes such as tricarboxylic cycle, fatty acid 
oxidation, the urea cycle, 
amino acid metabolism, 
heme synthesis, and FeS 
center assembly. Other 
effects of mitochondrial ROS 
include release of 
cytochrome c to the cytosol 
via the mitochondria outer 
membrane permeabilization 
(MOMP) and activation of 
the apoptotic machinery, 
induction of mitochondrial Figure 2.21. Mitochondrial ROS leads to oxidative damage of 
mitochondrial proteins, lipids, DNA, modulation of signaling pathways, 
and pathologies. Images from Murphy and coworkers.50 
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Figure 2.22. (A–B) Ferroptocide induces 
dose-dependent ROS generation within 1 
hr similar to positive control TBHP in 
ES-2 and in HCT 116 cells respectively. 
DMSO and etoposide were included as 
negative controls. Data are representative 
of three independent experiments. 
permeability transition pore (PPT) that increases susceptibility to ischemia and reperfusion 
injury, and modulation of redox signaling as shown in Figure 2.21. 61 
2.7.4.1 Ferroptocide causes ROS 
Given the importance of reactive oxygen species (ROS) generation in mitochondria, ROS 
levels were monitored upon compound treatment using a ROS probe, carboxy-H2CMFDA. 
Dose-dependent ROS production was observed in ES-2 (Fig. 2.22A) and HCT 116 cells treated 
with ferroptocide (Fig. 2.22B), similar to the positive control, tert-butyl hydroperoxide (TBHP) 
suggesting induction of oxidative cell death. To further investigate this hypothesis, protection 
studies with N-acetylcysteine (NAC-1) and a lipophilic antioxidant, trolox, were conducted in        















2.7.4.2 Antioxidant protection studies 
As shown in Figure 2.23. both antioxidants (NAC-1 and Trolox) significantly rescue 
cancer cells upon dose-dependent treatment with ferroptocide (10, 25, 50 µM). A similar 
observation is made upon treatment with the positive control TBHP, while pre-treatment of cells 
with these antioxidants did not protect them against the apoptotic agent, Raptinal. These data are 
suggestive of a type of oxidative cell death induced by ferroptocide, requiring further 
investigation. 




2.7.5 Ferroptocide is a pro-ferroptotic agent 
2.7.5.1 Ferroptocide induces lipid ROS 
As described in chapter one of this thesis, one non-apoptotic mode of cell death that 
depends on production of lethal levels of iron-dependent lipid ROS is ferroptosis, a regulated 
process with distinct morphological, biochemical, and genetic characteristics.62-66 The hallmarks 
of ferroptosis include generation of lipid hydroperoxides and cytoprotection by lipophilic 
antioxidants (trolox, butylated hydroxyltoluene [BHT]), ferroptosis inhibitors (ferrostatin-1, 
liproxstatin), and iron chelators (deferoxamine [DFO], ciclopirox olamine [CPX]).62 Cellular 
effects of ferroptocide-induced ROS were investigated using a C11-BODIPY probe that detects 
lipid peroxidation.63 Ferroptocide induces lipid ROS in ES-2 cells (Fig. 2.25 A), HCT 116 (Fig. 
2.25 B), and 4T1 cells (Fig. 2.25 C) similar to known ferroptosis inducer, (1S,3R)-RSL3 
(hereafter RSL3, Fig. 2.24)67; DFO pre-treatment of ES-2, HCT 116, and 4T1 cells protected 
them from ferroptocide- and RSL3-induced lipid ROS.  
Figure 2.23. Antioxidant probes rescue cells from ferroptocide-induced cell death.  NAC-1 (5 mM, 1 hr pre-
treatment) protects cells from ferroptocide treatment for 24 hr in (A) ES-2, (B) HCT 116 and (C) A549 cells. (D–F) 
Lipophilic antioxidant Trolox (250 µM) rescues A549, ES-2, and HCT 116 cells from ferroptocide-induced 
cytotoxicity after 12, 14, and 10 hr incubation respectively. Data are plotted as the mean ± s.d., n=3 biological 
triplicates. **** p < 0.0001, *** 0.0001 ≤ p < 0.001, ** 0.001 ≤ p < 0.01, *0.01 ≤ p < 0.05, n.s. p > 0.05. 
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2.7.5.2 Protection studies with ferrostatin-1 and DFO 
Given that generation of continuous lipid ROS is a functional requirement of 
ferroptosis,62,63 additional experiments were performed to elucidate if ferroptosis was triggered 
by ferroptocide. Protection studies were conducted with ferrostatin-1 and DFO, and these 
inhibitors significantly protected against ferroptocide-induced cell death in ES-2, HCT 116, 
4T1, and A549 cancer cells (Fig. 2.26 A–E, respectively). Additionally, these inhibitors rescued 
cells from the known ferroptosis inducers erastin (Fig. 2.26 A–B) and RSL3 (Fig. 2.26 C–F) 
respectively, while displaying no protection against Raptinal, an apoptosis-inducing agent. Taken 
together, these studies indicate that iron-dependent accumulation of lipid peroxidation 
(ferroptosis) upon ferroptocide-treatment is the cause of cell death.  
 
 














Figure 2.25. Ferroptocide induces lipid ROS. Ability of 
iron chelator deferoxamine to prevent ferroptosis upon 
treatment with ferroptocide or positive control RSL3 (10 µM) 
for 1 hr in ES-2 cells, 2 hr in HCT 116 cells, and 4 hr in 4T1 
murine cells. C11-BODIPY probe was utilized to detect lipid 
ROS. TBHP was used as a positive control upon 6 hr 
treatment. Data is representative of three independent 
experiments. 
 










Figure 2.26. Ferroptocide is a ferroptotic agent. (A, C, E, F). Ability of ferroptosis inhibitor, ferrostatin (2 
µM), to protect cells against ferroptocide treatment after 14 hr in ES-2, 24 hr in HCT 116, 18 hr in 4T1, and 12 
hr in A549 cells respectively. (B, D, E, F). Effect of ferroptosis inhibitor, deferoxamine (100 µM) on viability of 
ES-2 cells, HCT 116, 4T1, and A549 cells after 14, 24, 18, 12 hr incubation with ferroptocide and erastin 
(positive control) respectively. Data are plotted as the mean ± s.d., n=3 biological triplicates. **** p < 0.0001, 
*** 0.0001 ≤ p < 0.001, ** 0.001 ≤ p < 0.01, *0.01 ≤ p < 0.05, n.s. p > 0.05. 
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2.7.5.3 Head-to-head comparisons with Erastin and RSL3 
Erastin and RSL3 were originally discovered as small molecules with RAS-selective 
lethality.63 However, in our hands, the use of these tool compounds as positive controls for the 
ferroptosis studies described above revealed inconsistencies depending on the cell line. We set 
out to investigate the robustness of these compounds and ferroptocide. Monitoring the speed of 
cell death of ferroptocide versus erastin and RSL3, in HCT 116 and A549 cell lines (containing 
oncogenic K-RAS), demonstrates that ferroptocide is a fast-acting, robust pro-ferroptotic agent 
causing more quantitative cell death than the other two tool compounds (Fig. 2.27). This 
suggests that ferroptocide is a practical pro-ferroptotic tool compound that can be used reliably 
regardless of the cell line type.  
Additionally, treatment of HCT 116 cells with the same concentration of ferroptocide, 
RSL3, and erastin results in generation of similar levels of lipid ROS upon ferroptocide and 
RSL3 treatment and a larger quantity compared to erastin-treatment, suggesting a rapid onset of 




Figure 2.27. A–B. Ferroptocide is a robust pro-ferroptotic agent. Comparison of speed of cell death of 
ferroptocide, RSL3, and erastin, each at (10 µM) in HCT 116 and A549 (K-RAS mutant cell lines) 
















2.7.5.4 RNA-seq studies with Ferroptocide 
Genetic methods for target identification and validation are increasingly incorporated in 
drug discovery projects due to the unparalleled advances in RNA interference (RNAi),68 
si/shRNA screens69, and CRISPR Cas technologies.70,71 One key advantage of utilizing RNA 
sequencing to investigate compound-induced changes at the transcript level is the lack of 
chemical modification needed for the compound of interest. The ability to receive a snapshot of 
genetic modulations occurring at the transcript level upon compound treatment is extremely 
powerful and can guide target discovery efforts as demonstrated for the polo-like kinase 1 
(PLK1) inhibitor BI 2356.  HCT 116 compound-resistant clones were sequenced and compared 
to the parental line to reveal PLK1 gene as the main gene mutated in more than one group with 
specific mutations at the BI 2356 binding site.72  
We set out to monitor the effect of ferroptocide at the transcript level using genomic 
methods. RNA-seq data of ferroptocide-treated cells revealed that 35/40 genes involved in 
Figure 2.28. Generation of lipid ROS in HCT 116 cells upon 2 hr treatment using C11-bodipy 
probe for detection, n=3 biological replicates. DMSO is used as a negative control. 
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ferroptosis are modulated after 6 hr treatment in HT-29 colon cancer cells with false discovery 
rate (FDR) scores ≤ 0.05 (Fig. 2.29 A). This time point was selected to capture the primary 
mechanisms of the compound of interest on viable cells as described previously.73 HT-29 cell 
viability was assessed via AV/PI analysis upon ferroptocide-treatment (Fig. 2.29 B).  
Specific genes such as GCLC (3.5 fold), GCLM (4.9 fold), SLC7A11 (8.1 fold), and 
CHAC1 (9.8 fold), known to be upregulated in ferroptosis,62,74 and AFT3 (11.5 fold), DDIT3 
(22.5 fold), DDIT4 (11.3 fold), known to be upregulated upon ferroptosis were significantly 
overexpressed after ferroptocide-treatment, similar to  RNA-seq results previously reported for 
erastin in HT-1080 cells.74 Pathways affected by oxidative stress such as Keap1-Nrf2 (p=7.8 10-
10), unfolded protein response (p=3.6 10-8), protein processing in endoplasmic reticulum (p=2.4 
10-10), amino acid transmembrane transporter activity (p=1.7 10-5), and others were also modified 
upon compound treatment (Fig. 2.30 A, B). A detailed list of the top 30 upregulated genes and 
top 25 downregulated genes can be found in the general methods of this chapter (Table S1, S2 
respectively). These transcription profiles further support the hypothesis that ferroptocide 
























Figure 2.29. (A) Modulation of 35/40 genes involved in ferroptosis upon 6hr treatment of HT29 cells with 
10 µM ferroptocide (FDR ≤ 0.05). (B) AnnexinV/PI graphs of HT-29 cells treated with ferroptocide (10 µM) 




Figure 2.30. (A) Upregulation of KEAP1-Nrf2 pathway in ferroptocide-treated HT-29 cells. (B) Modulation 
of oxidative-stress pathways upon ferroptocide treatment, RNA-seq data of HT-29 cells. 
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2.8 Additional studies 
2.8.1 Cell cycle studies 
Cell cycle studies enable investigation of the overall effect of a cytotoxin in a specific 
phase of the cell cycle machinery. Information on disruption of a specific cell cycle phase 
provides insights and potential leads for mode of action studies. Propidium iodide (PI) dye is 
used to stain DNA of the fixed cells and asses if the compound effect (amount of PI signal) is 
localized in phase one (G1), two (G2/M), or synthesis phase (S).  
Treatment of suspension cells (U-937) and adherent cells (ES-2) with dose-dependent 
concentrations of ferroptocide resulted in S-phase arrest as observed in Figure 2.31 similar to 
the effect seen after treatment with the S-phase arrestor75 doxorubicin. On the other hand, 
treatment of cells with Taxol caused arrest of cells in G2/M phase, consistent with literature 
reports.76  
Additionally, time-course and G1-phase cell cycle synchronization studies of U-937 cells 
upon treatment with ferroptocide supported the S-phase arrestor observations (Fig. 2.32 A, B 
respectively). These data suggest that ferroptocide is not a microtubule stabilizer or destabilizer 
as observed from the lack of G2/M arrest but can potentially modulate a target that is implicated 
in DNA synthesis and causes S-phase arrest.  
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Figure 2.31. Ferroptocide is a S-phase arrester. (A–B) Cell cycle distribution of U-937 and ES-2 cells 
after 8 hr and 7 hr compound treatment respectively. The data was collected via flow cytometry (PI) and are 






Figure 2.32. (A) Time course treatment of U-937 cells with 5 µM ferroptocide and 500 nM doxorubicin (Dox) at 
the indicated time points. Data are plotted as the mean ± s.e.m., n=3 biological replicates. (B) G1-cell 
synchronization studies. U-937 cells were starved for 24 hr with 0.2% FBS and then treated with 5 µM ferroptocide 
and 500 nM doxorubicin (Dox) for each specified time point. Data were collected via flow cytometry (PI) n=2. 
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To further investigate this hypothesis, we monitored the ability of ferroptocide to 
intercalate DNA and induce DNA damage. S-phase arrestor drugs can be categorized into 
topoisomerase inhibitors (i.e. etoposide, irinotecan, doxorubixin, daunoriubicin etc.), alkylating 
agents (Pt-agents), nucleoside analogues (gemcitabine, 5-FU), and DNA cleaving agents/minor 
grove binders (temoporfin, photopinantrin etc.) among a few others. Specific assays tailored to 
monitor the effect of each class are commercially available and were employed to assess the 
effect of ferroptocide. As shown in Figure 2.33, ferroptocide does not intercalate DNA similar 
to etoposide, while doxorubicin intercalates by displacing ethidium bromide, thus suggesting that 
our lead compound is not a DNA-intercalator.   
Figure 2.33. Ferroptocide is not a DNA-intercalator. Dose-dependent incubation of Herring DNA with ferroptocide, 
etoposide and doxorubicin for 30 min at r.t. Fluoresence was measured at Ex=300nm and Em= 590 nm in Gemini at 
IGB. Data are plotted as the mean ± s.e.m., n=3 biological replicates. 
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To further explore the effect of ferroptocide on DNA synthesis, its ability to induce 
DNA damage was assessed via flow cytometry and western blot analysis, monitoring for DNA 
damage markers such as gamma H2AX (ɣ-H2AX). This marker is correlated with the production 
of DNA double strand breaks, which are lethal to cells. As demonstrated in Figure 2.34, 
ferroptocide-treatment of ES-2 cells causes generation of ɣ-H2AX in a dose-dependent manner 
similar to the positive control gemcitabine. Collectively, the additional studies indicate that 
ferroptocide is an S-phase arrester that does not intercalate DNA, and directly or indirectly 
modulates a key target in DNA synthesis, resulting in generation of double stranded breaks. 
Other ferroptosis-inducers have not been reported to cause DNA damage; more experiments are 

















Figure 2.34. Ferroptocide generates double stranded breaks. (A) Monitoring the ability of ferroptocide to cause 
DNA damage in ES-2 cells after a 5 hr-incubation. Gemcitabine was used as a positive control after a 20 hr 
treatment. Data is representative of 4 independent biological experiments. (B) Western blot analysis of ferroptocide 
and control compounds to induce ɣH2AX in ES-2 cells after 5 hr and 20 hr treatment respectively, n=2. 
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2.9 Target ID and validation studies 
2.9.1 Covalent binding in cells  
SAR trends reveal that ferroptocide bioactivity depends on the presence of the 
electrophilic α-chloroester (Fig. 2.7), suggesting the possibility that it covalently modifies its 
target. To assess covalent modification in cells, in-gel fluorescence studies were performed in 
conjunction with competition studies. Treatment of cells with increasing concentrations of 
fluorescent analogue P30 resulted in labeling of five main bands (Fig. 2.35A). Pre-treatment of 
cells with various concentrations of ferroptocide, followed by treatment with compound P30 
resulted in dose-dependent competition, primarily of two bands, in the in-gel fluorescence assay 
(bands B and D in Fig. 2.35B) implying specific compound interaction.  A similar labeling and 
competition pattern was observed in multiple cancer cell lines including HCT 116, U937, BT-
549, T47D, MDA-MB-231 (Fig. 2.36A), and primary cancer cells from patients (Fig. 2.36B). 
This finding suggests modulation of the same targets in immortalized cancer cell lines and in 
primary cancer cells. Next, we set out to identify these bands of interest. 
Figure 2.35. Ferroptocide is a covalent inhibitor in cells. (A) Proteomic profile for fluorescent analogue 
P30 in HCT 116 cells after 60 min treatment reveals labeling of five main bands. (Note: Band A and A’ 
often appear as one band). Coomassie stain of gel demonstrates equal loading (Supplementary Fig. 2.1A). 
(B) Competitive profiling of the proteomic reactivity of P30 with parent compound ferroptocide. HCT 116 
cells were pre-treated with DMSO or various concentrations of ferroptocide (30 min) followed by 
treatment with P30 (1 µM, 30 min) and analyzed by in-gel fluorescence assay. Specific competed proteins 




Figure 2.36. (A) Ferroptocide covalently modifies the same target(s) in multiple cell lines. Competition experiments 
were performed by treatment of cells with DMSO or ferroptocide (20 µM, 30 min) followed by P30 incubation (1 
µM, 30 min) and then analyzed using an in-gel fluorescence assay. Images are representative of three biological 
replicates. Coomassie stain of gels demonstrates equal loading (Supplementary Fig. 2.1C). (B)  Ferroptocide causes 
the same proteomic competitive profile in primary cells isolated from metastatic cancer patient samples. Competition 
experiments were performed by treatment of cells with DMSO or ferroptocide (20 µM, 30 min) followed by P30 
incubation (1 µM, 30 min) and then analyzed using an in-gel fluorescence assay. Representative images of two 
biological replicates. PPC: primary peritoneal carcinomatosis. Coomassie stain of gels demonstrates equal loading 
(Supplementary Fig. 2.1D). 
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2.9.2 Chemical proteomics: 1D Gel  
Chemical proteomics, specifically in-gel fluorescence studies, are well-characterized target 
identification methods that have been widely utilized to identify the target of many small 
molecule compounds such as pyrrolidine 1 (fumarate hydratase inhibitor),77 1,3,5 triazine RB-
11ca (protein disulfide isomerase inhibitor),78 and curcumin (casein kinase I gamma).79, In an 
attempt to elucidate the target of interest, protein identification via mass spectrometry was 
coupled with in-gel fluorescence (workflow shown in Fig. 2.37). Briefly, cells were incubated 
with compound P30 and lysed before proteins were separated by SDS-PAGE, then subjected to 
in-gel fluorescence studies. Fluorescent bands were manually excised, trypsin-digested, and 




Figure 2.37. Chemical proteomics workflow for target ID in 1D gels.  
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2.9.3 Mitochondrial fractionation   
As showcased in Figure 2.36. treatment of whole cells with ferroptocide followed by 
fluorescent analogue P30 resulted in predominant competition of two bands, B and D, suggesting 
specific compound interaction. We set out to identify the protein target(s) corresponding to band 
B using chemical proteomics. Cell fractionation was employed to investigate if any of the 
potential proteins were associated with mitochondria from MOA studies. Indeed, the strongest 
fluorescent signal was observed in the membrane/organelle fraction (Fig. 2.38A–B), implying 
compound activity in mitochondria, consistent with confocal microscopy and TEM images (Fig. 
2.19).  
 
To further explore this hypothesis, mitochondria of HCT 116 and ES-2 whole cells treated 
with P30 were isolated. A similar fluorescence pattern was observed in whole cells for both cell 
lines (Fig. 2.38 A–B). The most intense fluorescent band that was competed away was excised 
Figure 2.38. (A) Cell fractionation of HC T116 cells was subjected to in-gel fluorescence studies. Treatment with P30 
results primarily in labeling of mitochondrial proteins. (B) Cell fractionation of ES-2 cells treated with fluorescent 
analogue P30 indicates labeling of mitochondrial proteins. Each gel is representative of three independent biological 
replicates. Coomassie stain of gels demonstrates equal protein loading. 
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and analyzed via LC–MS/MS. The analysis provided a list of 12 and 45 proteins detected 
between 25-37 kDa for HCT 116 and ES-2 cells, respectively (Table 2.3). However, only two 
proteins were present in both cell lines: a putative protein (unknown) and F-ATPase F1 
mitochondrial complex gamma subunit. Compound modification was not observed in any of the 
peptides of interest, likely due to low protein coverage of < 30%, thus warranting investigation 













Figure 2.39. In-gel fluorescence studies coupled to chemical proteomics. Whole cells pre-treated 
with ferroptocide (20 µM, 30 min) followed by P30 incubation (1 µM, 30 min) were subjected to 
mitochondrial fractionation and then analyzed via in-gel fluorescence assay. Fractions 1 and 2 were 
excised and submitted for LC–MS/MS analysis. n=2 biological replicates. 
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Table 2.3. Top-scored protein candidates identified from the 1D mitochondrial gel of HCT 116 and ES-2 cells. 
12 Proteins in HCT116 (F1) 45 Proteins in ES-2 (F1) 
Putative 553734 Unnamed protein product 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, gamma 
polypeptide 1 
Chain A, Human Annexin V with Incorporated 
Methionine Analogue Azidohomoalanine 
Unnamed protein product Unnamed protein product 
hCG2045732 Unnamed protein product, partial 
GAS2-like protein 2 Unnamed protein product 
HSPC303 hCG2028724 
V12-13 Cytokeratin 9 
Zinc finger protein 445 L-lactate-dehydrogenase B chain 
synaptophysin 60S ribosomal protein L8 
Tetratricopeptide repeat protein 28 Putative 553734 
RecName: FAM201A BBC1 
Predicted: AT-rich interactive domain-
containing protein 1B isoform X4 
L-lactate-dehydrogenase A chain 
60S ribosomal protein L13 isoform1 40S ribosomal protein S6 
 ATP synthase, H+ transporting, mitochondrial F1 
complex, gamma polypeptide 1 
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2.9.4 2D-gel target ID studies   
A two-dimensional gel electrophoresis (2D-PAGE) strategy was incorporated to narrow 
down the number of candidate protein target(s) and improve the resolution of 1D in-gel analysis. 
2D-PAGE is a robust  method to readily detect changes in protein levels between different 
samples.80,81  Proteins are initially separated by the isoelectric point (pI) in the first dimension, 
followed by molecular weight (MW) via SDS–PAGE in the second dimension; thus, only 
proteins with the same isoelectric point and molecular weight are present in an isolated spot of a 
2D gel.  
2.9.4.1 Fluorescence pattern in a 2D-gel   
Attempting to exploit the high sensitivity of 2D-PAGE to separate proteins of the same 
molecular weight and pI, HCT 116 whole cell extracts were subjected to a 2D in-gel 
fluorescence analysis as shown in Figure 2.40. Gratifyingly, the pattern of fluorescence in the 
2D gel is consistent with the 1D gel indicating that fluorescent analogue of ferroptocide, P30, is 
targeting specific proteins. Pre-treatment of HCT 116 cells with ferroptocide resulted in 
diminishment of only one of the fluorescent signals in the 2D gel suggesting non-specific 
compound labeling (Fig. 2.40) of the other two bands. Excision of the bands of interest (marked 
in red Fig. 2.40) followed by tryptic digestion and LC–MS/MS analysis (LTQ-Orbitrap in 
positive ionization mode) afforded a list of over 150 potential protein targets. Efforts to monitor 
the P30-induced chemical modification of the peptides of interest were unsuccessful potentially 
due to compound fragmentation and/or lack of sample ionization in the positive electrospray 






Figure 2.40. Separation of proteins from HC T116 cells treated with P30 (1 µM, 30 min) by molecular and 
isoelectric point. The fluorescent gel was stained with Sypro Ruby and existed at the bands of interest (S1, 




2.9.4.2 Compound fragmentation pattern in LC–MS/MS 
To further explore this hypothesis, MS/MS analysis of compound alone (P30), and P30 
adduct with glutathione was monitored. This study revealed a unique fragmentation pattern 
where the α-chloroester is lost during LC–MS/MS analysis as shown in Figure 2.41, resulting in 
a 58 Da modification shift. Given the propensity of ferroptocide to react with nucleophilic 
amino-acids including cysteine, serine, tyrosine and threonine in a similar fashion as with 
glutathione, such residues were examined for a + 58 Da mass increment corresponding to 
compound reactivity.  
 
 
Figure 2.41. Compound (P30) fragmentation pattern in LC–MS/MS upon reactivity with glutathione for 24 hr. 
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2.9.4.3 Candidate protein targets from 2D-gel analysis  
Investigation of proteins that contain a 58 Da modification in their cysteine residues resulted 
in identification of four potential candidate proteins (Table 2.4). From this selected list, electron-
transport flavoprotein (ETFA), showed significantly higher spectral count scores in all three 
samples, and thus was further evaluated as a putative target. Figure 2.42 showcases the 58 Da 
shift of a cysteine residue of ETFA as observed from LC–MS/MS analysis implying covalent 
modification of ETFA from the compound of interest. emPAI is a metric for measuring protein 
coverage while the ion score is a measure of how well the observed MS/MS spectrum matches 
the database peptide sequence. High emPAI and ion score values represent high confidence and 
significance of the data set. Comparison of the potential targets identified from the 2D gel 
analysis (Table 2.4) was inconsistent with the data set obtained from the mitochondria isolated 
bands in the 1D gel. Such discrepancies could be attributed to potential sample contamination 
during work up, different facilities, and drastically different staining methods and 
instrumentations. 









S1       S2        S3 
Electron-transfer flavin 
alpha 
33 61 58 3 8.62 8.77 3.58 2.55 
Actin related 2/3 complex 
subunit 
34 49 54 NA 6.84 13.76 20.29 2.40 
Pyrroline-5-carboxylate 
reductase 
33 19 NA 26 7.18 4.14  3.00 13.09 
Guanine-nucleotide 
binding beta 
35 10 34 22 7.60 3.74 6.65  4.34 
 
 
NA (no modification) 
S1: sample 1, S2: sample 2, S3: sample 3 
emPAI: exponentially modified protein abundance index 
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Figure 2.42. LC–MS/MS representative chromatogram of the 58 Da shift of the ETFA peptide at the cysteine 











2.9.5 Target validation from 2D-gel analysis 
2.9.5.1 Role of ETFA in Cells 
ETFA is a 30 kDa subunit of the electron transfer flavoprotein (ETF), which is localized 
at a strategic position in the mitochondrial respiratory chain (Fig. 2.43) and shuffles electrons 
from 9 different binding partners such as acetyl-CoA, isovaleryCoA, Glutaryl-CoA, and 
Sarcosine dehydrogenase to the main mitochondrial respiratory chain via ETF-ubiquinone 
oxidoreductase.82,83 ETFA is vital for the mitochondrial fatty acid oxidation and metabolism of 
normal amino acids. Mutations or deficiencies in ETFA (as well as the other subunit, ETFB) lead 
to an inherited metabolic disorder named glutaric aciduria type II, which impairs processing of 
proteins and fatty acids resulting in their buildup and metabolic acidosis (tissues and blood 
become too acidic).84,85  
 
Figure 2.43. Schematic of the position and function of ETFA in the mitochondria respiratory chain.  
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2.9.5.2 Immunoprecipitation studies using BODIPY antibody 
To investigate ETFA as a potential target of P30, immunoprecipitation studies were 
conducted (Fig. 2.44). In brief, HCT 116 and ES-2 cells were treated with DMSO, BODIPY 
azide, P30 (1 µM, 30 min), lysed and exposed to magnetic beads pre-incubated overnight with a 
BODIPY antibody for 15–24 hr at 4 degrees. Upon elution of BODIPY antibody-compound-
protein complex, samples were subjected to in-gel fluorescence studies followed by western blot 
analysis with an ETFA specific 
antibody. BODIPY azide served 
as a control for non-specific 
binding to the BODIPY 
fluorophore, while DMSO was a 
control for non-specific binding 
to Dynabeads (magnetic beads).  
As observed in Figures 2.45 and 2.46, immunoprecipitation studies were successful in 
both cell lines without interference from non-specific binders. Figure 2.46 displays the ability of 
a BODIPY antibody to pulldown ETFA from HCT 116 cells treated with P30 suggesting 
modification of ETFA by our compound of interest. Competition pull down studies revealed 
competition of the specific band at 10 kDa but not at 25 kDa (a target different than ETFA). 
Nevertheless, investigation of the ability of ETFA antibody to colocalize with the fluorescent 
signal of compound P30 were not successful, implying a weak ETFA–P30 interaction. 




Figure 2.45. Immunoprecipitation studies with a BODIPY antibody in ES-2 cells. Upon 30 min 
treatment of cells with P30 (1 µM), DMSO, BODIPY azide (1 µM), 100 µg protein samples were co-
incubated with anti-rabbit IgG Dynabeads coated with BODIPY antibody and eluted for in-gel 
fluorescence studies and western blot analysis. The elution lane indicates successful pull down of 




2.9.5.3 CETSA ETFA and Ferroptocide  
Cellular thermal shift assay (CETSA) is a novel method used to monitor target 
engagement in cells. CETSA evaluates the change in melting temperature of the protein target in 
the presence or absence of the small molecule upon thermal denaturation.86-88 This technique is 
based on the principal that binding of a compound to the protein of interest results in a 
conformational change which can stabilize the protein complex and protect it from thermal 
denaturation. Despite the initial promise for use of CETSA as a target identification method, its 
potential has only been demonstrated in validating well-known or hypothesized targets, which 
Figure 2.46. Immunoprecipitation studies with a BODIPY or ETFA antibody in HC T116 cells. Upon 30 
min treatment of cells with P18 (20 µM), DMSO followed by 30 min incubation with P30 (1 µM), 100 µg protein 
samples were co-incubated with anti-rabbit IgG Dynabeads coated with BODIPY/ETFA antibody and eluted for 
in-gel fluorescence studies and western blot analysis. Fluorescent bands were observed with the BODIPY 
pulldown but not with ETFA suggesting weak binding between P30 and ETFA. Gel image is representative of 
three independent biological replicates. 
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must not melt at high temperatures. In addition, this approach has yet to be optimized for 
membrane targets.  
CETSA was performed to monitor the ferroptocide-ETFA target engagement in cells. 
Treatment of ES-2 cells with DMSO, ferroptocide, and inactive analogue P24 resulted in a 
small 3 degrees difference in melting temperature values as shown in Figure 2.47. Actin levels 
were monitored for equal protein loading (LDHA protein is a more suited CETSA control since 
it melts at high temperatures, >90°). Given the insignificant change in the melting temperatures 
between DMSO & ferroptocide-treated samples, additional target validation studies needed to 





Figure 2.47. Ferroptocide weakly binds to ETFA in ES-2 cells to stabilize it against thermal denaturation. Cells 
were treated with DMSO, ferroptocide (20 µM), and inactive analogue P24 (50 µM) for 30 min. Samples were 
subjected to 3 flash freezing cycles with liquid nitrogen in the presence of a protease inhibitor cocktail followed by 
western blot analysis with ETFA antibody. Actin protein was monitored for equal protein loading. Immunoblots are 
representative of n=2 out of 4 biological replicates. 
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2.9.5.4 siRNA and CRISPR KO ETFA studies  
Another validation method are genetic knockdown studies using siRNA. Upon siRNA 
knockdown of ETFA in HCT 116 cells for 72 hr, cells were treated with DMSO or ferroptocide 
for 30 min followed by 30 min P30-treatment and assessed for changes in the fluorescent signal 
between wild type and siRNA transfected cells. Quantitative knockdown of ETFA in cells (> 80 
%, Fig. 2.48) did not result in any fluorescent changes in the in-gel fluorescence studies, 
suggesting that ETFA is not the target of interest. Exposure of HCT 116 cells with knockdown 
levels of ETFA to ferroptocide in a time-course study (Fig. 2.49) yielded inconsistent results 
towards protection against compound-induced cell death, thus requiring further investigation.  
Figure 2.48. siRNA knockdown of ETFA in HCT 116 cells results in no change of the fluorescent labeling as 
shown by the red arrow. (A) Wild type and siRNA transfected cells were subjected to competition 
experiments with ferroptocide (20 µM) 30 min pre-treatment followed by P30 (1 µM) 30 min treatment and 
in-gel analysis. Coomassie gel indicates equal protein loading. (B) Immunoblot of ETFA and GAPDH 
(siRNA positive control) of same cells shows a successful know down experiment. Data are representative of 
n=3 biological replicates.    
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To confirm ETFA as a non-target of ferroptocide, we turned to CRISPR KO studies. The 
in-gel fluorescence studies with HCT 116 cells lacking the ETFA protein show no change in the 
fluorescent labeling pattern compared to studies in wild type cells, thus concluding that ETFA is 
not the target of interest, band B (Fig. 2.50). Cell death studies with CRISPR KO cells protect 
against ferroptocide-induced cell death as shown in Figure 2.51. This finding suggests that 
ETFA is an off-target protein that could mediate ferroptocide-induced cell death. There are no 
reports to date that implicate ETFA in ferroptosis. In retrospect, inability of an ETFA antibody to 
isolate the P30 fluorescent signal and inconsistency of CETSA results support the hypothesis 
that ETFA is not the target of interest. Nonetheless, CRISPR KO studies provided the most 
conclusive evidence and must be prioritized in small molecule target validation efforts 
Figure 2.49. Monitoring the ability of siRNA transfected HCT 116 cells to protect against ferroptocide-
induced (10 µM) cell death at the indicated time points. Annexin V/PI analysis was utilized to assess cell death 
via flow cytometry. Immunoblots of the same cells used for flow analysis assess the efficiency of siRNA 




Figure 2.50. CRISPR knockout of ETFA in HCT 116 cells results in no change of the fluorescent labeling as 
shown by the red box. (A) Wild type and CRISPR KO cells were subjected to competition experiments with 
ferroptocide (20 µM) 30 min pre-treatment followed by P30 (1 µM) 30 min treatment and in-gel analysis. 
Coomassie gel (botom gel) indicates equal protein loading. (B) Immunoblot of ETFA and Actin (loading control) 
of same cells confirms successful knockout of ETFA in cells. Data are representative of n=3 biological replicates.    
Figure 2.51. Monitoring the ability of ETFA KO clones to protect against 10 µM ferroptocide-induced cell death 
upon 24 hr incubation. Raptinal (10 µM) is used as a positive control. Annexin V/PI assessment was performed 
via flow cytometry. Data represents the average cell death of two biological replicates. 
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2.9.6 Target ID: Biotin-streptavidin pulldown  
In an effort to identify the labeled protein(s), a biotin-streptavidin pulldown78 (Fig. 2.52 
A) was performed with the bioactive alkyne compound P29 in collaboration with professor 
Eranthie Weerapana at Boston College. Briefly, HCT 116 cells were pre-treated 
with ferroptocide or DMSO, followed by treatment with P29. Upon incorporation of biotin 
using copper-catalyzed azide-alkyne cycloaddition (CuAAC) chemistry, P29-labeled proteins 
were enriched on streptavidin beads, subjected to an on-bead trypsin digestion and subsequent 
LC/LC–MS/MS analysis.  
Protein identities were determined by database searches using the SEQUEST algorithm. 
Relative quantitation of proteins enriched in ferroptocide or DMSO pre-treated samples was 
achieved by spectral counting. The DMSO/ferroptocide spectral count ratio provides a relative 
measure of enriched proteins in the DMSO versus ferroptocide pre-treated samples (Fig. 
2.52B). High-affinity targets from the HCT 116 cell line were then compared to targets identified 
in a second cell-line ES-2. Based on shared enrichment in both cell lines, as well as comparing 
protein molecular weights to the bands observed in in-gel fluorescent gel, nine proteins were 





Table 2.5. Proteins identified for follow-up characterization that had shared enrichment in both HCT 116 and ES-2 














TXNRD3 76.4 7.4 
TXNRD1 70.8 4.9 
KEAP1 69.7 3.1 
PDP1  61.1 3.7 
TXNRD2 56.4 2 
PTGES2 41.9 18 
PGLS 27.5 2.7 
GSTO1 27.5 3.6 
TXN  11.7 11.1 
Figure 2.52. (A) Schematic of biotin-streptavidin pulldown method: Treatment of HCT 116 cells with ferroptocide (30 
min) and P29 (60 min) was followed by CuAAC reaction with biotin-azide and enrichment with streptavidin magnetic 
beads. On-bead trypsin digestion coupled to LC/LC–MS/MS provided a list of over 300 targets. (B) Enrichment of 




2.9.7 siRNA and CRISPR KO studies of putative targets 
In order to discriminate between on- and off- cytotoxicity-related targets, siRNA and 
CRISPR Cas9 strategies were employed. KEAP1 and GSTO1 proteins were targeted first since 
they possessed molecular weights similar to bands A and B respectively. Upon successful 
knockdown of these proteins (Fig. 2.53B), an assessment was made of how changes in protein 
expression affected band labeling in the in-gel fluorescence experiment. Comparison of cells 
with knockdown targets and wild type cells indicated no change in in-gel fluorescence (Fig. 
2.53A), suggesting that KEAP1 and GSTO1 are off-pathway targets of ferroptocide.  
CRISPR Cas9 technology was then used to rapidly investigate the remaining targets. We 
were able to successfully generate isogenic cell line pairs for seven knockout targets, with one 
target knockout leading to lethality. Knockout of six targets (PTGES2, PGLS, TXNRD1, 
TXNRD2, TXNRD3, and PDP1) did not diminish labeling of any of the fluorescent bands 
indicating that these proteins were not the targets of interest; the lethal target was thioredoxin 
protein (Fig. 2.53C).  
Additionally, the same cell line pairs were subjected to cell viability studies using 
Annexin V/PI analysis upon 24 incubation with the compounds of interest. As shown in Figure 
2.54, HCT 116 cells lacking thioredoxin reductase 2 (TXNRD2) and thioredoxin reductase 3 
(TXNRD3) conferred modest protection against ferroptocide-induced cell death while cells 
without any PTGES2 protein afforded the highest degree of protection. These findings suggest 
that these targets could be relevant targets in the ferroptocide-elicited cell death pathway. The 
remaining targets such as PGLS, TXNRD1, and PDP1 appeared to have no effect in the 
ferroptocide-induced mode of cell death. Collectively, these results demonstrate that these 




Figure 2.53. (A)   Proteomic profiling of probe P30 (1 µM, 30 min) upon pre-treatment with DMSO or ferroptocide (20 
µM, 30 min) in HCT 116 cells after 72 hr siRNA transfection of GSTO1 and KEAP1 targets respectively. Coomassie 
stain of gels demonstrates equal loading (Supplementary Fig. 2.2). (B) Western blot analysis of siRNA knock-down 
efficiency. GAPDH is a positive control of transfection process and actin is a control of equal protein loading. (C) In-gel 
fluorescence scanning of CRISPR Cas9-generated isogenic cell lines for six targets in HCT 116 cells treated with DMSO 
or ferroptocide (20 µM, 30 min) followed by 30 min incubation with probe P30 (1 µM) and separation of proteins via 
SDS-PAGE gel. Coomassie stain of gels demonstrates equal loading (Supplementary Fig. 2.2). 
Figure 2.54. Protection studies with CRISPR KO clones of putative targets. HCT 116 cells lacking each of the 
specified proteins were treated with ferroptocide (10 µM), DMSO, and Raptinal (10 µM) for 24 hr. Cell viability 




2.9.8 Thioredoxin as a putative target of ferroptocide  
Thioredoxin is a 12 kDa ubiquitous oxidoreductase that plays a key role in the thioredoxin 
antioxidant system comprised of thioredoxin, NADPH, and thioredoxin reductase. This enzyme 
contains 5 total cysteines and uses its active site cysteines (positions 32 and 35) to reduce the 
disulfide bonds of many binding partners such as transcription factors (NF-κB, AP-1, Ref-1), 
ribonucleotide reductases, peroxiredoxins, and glutathione peroxidases in addition to scavenging 
reactive oxygen species as shown in Figure 2.55.89,90 In addition, thioredoxin is overexpressed in 
many cancers such as colon91, gastric92, renal93, lung, mesothelioma94 , non-small cell lung 
cancer95, hepatocellular carcinoma96, etc, so it is an attractive anticancer target in the clinic.  
Figure 2.55. Role of thioredoxin in cells. (A) Thioredoxin is a key protein in the thioredoxin antioxidant 
system in cells that plays a critical role in many cellular processes upon reduction of multiple binding 
partners such as AP-1, NFκB, ribonucleotide reductase, peroxiredoxins (Prx), glutathione peroxidases 
(Gpx) etc. (B) Mechanism of disulfide bond reduction via thioredoxin. The first step involves nucleophilic 
attack by Cys 32 to afford an intermediate sulfide bridge between thioredoxin and the binding partner 
followed by extraction of an H atom from cysteine 35 that results in reduction of the target of interest and 
oxidation of thioredoxin.   
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2.9.8.1 TXN pulldown  
To investigate thioredoxin as the potential target of ferroptocide, the alkyne probe was 
utilized to conduct a pulldown experiment. Treatment of HCT 116 cells with P29, coupled to 
biotin-streptavidin enrichment followed by immunoblotting yielded a band present only in 
compound treated sample as shown in Figure 2.56, suggesting that ferroptocide covalently 
modifies thioredoxin.  
 
2.9.8.2 TXN activity assay 
A thioredoxin activity assay was then employed to assess the ability of ferroptocide to 
inhibit thioredoxin activity in cell lysate, and this compound significantly reduced the activity of 
thioredoxin within 30 min of treatment in HCT 116 cells to a greater extent than the two known 
inhibitors of thioredoxin (PMX464 and PX-12)97-99 as shown in Figure 2.57A. Dose-response 
analysis confirmed that ferroptocide is also a more potent thioredoxin inhibitor than PMX464 
and PX-12 in a biochemical (in vitro) assay (Fig. 2.57B). 
Figure 2.56. Immunoblot of thioredoxin pulldown upon treatment of HCT 116 cells with DMSO or P29 (20 µM, 
60 min) followed by CuAAC reaction with biotin-azide and enrichment with streptavidin magnetic beads. 
Thioredoxin appeared only in the P29-treated samples. BPD (biotin pulldown) and input (soluble cell lysate 




Figure 2.57. Ferroptocide inhibits thioredoxin activity in cells and in vitro.  (A) Effect of ferroptocide (20 
µM) and known inhibitors PMX464 and PX-12 (50 µM) on thioredoxin activity in ES-2 cells after 30 min 
incubation. p-values are relative to DMSO control. (B) Comparing in vitro activity of ferroptocide and known 
thioredoxin inhibitors, PX-12 and PMX464 to inhibit purified human thioredoxin in a dose-dependent manner 
after 30 min treatment using a thioredoxin activity kit. Data are plotted as the mean ± s.d., n=3 biologically 
independent samples. p values are relative to DMSO control, **** p < 0.0001, *** 0.0001< p < 0.001, ** 
0.001< p < 0.01 * 0.01 ≤ p < 0.05, n.s. p > 0.05. 
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2.9.8.3 TXN overexpression 
Generation of thioredoxin CRISPR KO cells is lethal; thus, to further assess the effect of 
ferroptocide on thioredoxin, thioredoxin fused to GFP (TXN-GFP, 37kDa) was overexpressed 
in HCT 116 cells as imaged in the GFP channel (Fig. 2.58 A). Treatment of these cells with the 
alkyne probe P29, followed by bioconjugation of the orthogonal fluorophore of Cy3, afforded a 
new band at 37 kDa corresponding to TXN-GFP as visualized in the Cy3 channel (Fig. 2.58B). 
This new band was competed upon pre-treatment with ferroptocide for 30 min followed by 
alkyne treatment suggesting compound specificity for this target and strengthening the 





Figure 2.58.  Ferroptocide and its analogues bind to thioredoxin in cells. (A) In-gel fluorescence scanning of 
HCT 116 cells overexpressing TXN-GFP shows a new band (red arrow) at 37 kDa, wild type are non-transfected 
cells, GFP channel. Coomassie stain of gel demonstrates equal loading (Figure S3). (B) Competition profile of 
thioredoxin labeling by probe P29 (20 µM, 60 min) upon pre-treatment with DMSO or ferroptocide (20 µM, 30 
min) followed by CuAAC with Cy3 azide in HCT 116 cells overexpressing TXN-GFP plasmid vs. non-
transfected (wild type) cells, Cy3 channel. Red box indicates competition of the band of interest. Representative 
in-gel fluorescence images of n=3 biological replicates. Coomassie stain of gel demonstrates equal loading 
(Supplementary Fig. 2.3). 
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2.9.8.4 Site-directed mutagenesis 
To identify the sites of modification of thioredoxin by ferroptocide, site-directed 
mutagenesis was used to introduce serine mutants of each of the five cysteines of TXN-GFP. The 
ability of ferroptocide to covalently modify these mutant proteins was assessed after 
transfection of mutant clones (C32S, C35S, C62S, C69S, and C73S, Fig. 2.59A) into HCT 116 
cells, followed by pre-treatment of these cells with ferroptocide and subsequent alkyne 
treatment and Cy3 bioconjugation to evaluate band labeling via in-gel fluorescence assay. As 
shown in Figure 2.59B, the new band at 37 kDa is not present in the C32S and C35S mutants 
and has reduced labeling in the C73S mutant, suggesting that ferroptocide is modifying the 
active site cysteines and the adjacent cysteine 73 of thioredoxin as shown in the crystal structure 





Figure 2.59. Ferroptocide modulates active site cysteines of thioredoxin. (A) Assessing transfection 
efficiency of HCT 116 cells overexpressing C32S, C35S, empty GFP vector, C62S, C69S, and C73S mutants. 
WT are non-transfected HCT 116 cells. Data are representative of n=3, biological triplicates. (B) Identification 
of ferroptocide labeling sites of thioredoxin. In-gel fluorescence scanning of HCT 116 cells overexpressing each 
thioredoxin-mutated cysteine plasmid. Cells were pre-treated with DMSO or ferroptocide (20 µM, 30 min) 
followed by incubation with P29 probe (5 µM, 60 min) and then CuAAC reaction with Cy3 azide. The serine 
mutations of the active site cysteines 32, 35 and cysteine 73 diminished compound labeling. Data are 
representative of three independent experiments. Coomassie stain of gels demonstrates equal loading 
(Supplementary Fig. 2.4). (C) Crystal structure of thioredoxin with cysteine residues colored in red. 
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2.9.8.5 TXN and Ferroptosis 
Together, these studies demonstrate that treatment with ferroptocide modifies critical 
residues needed for interaction of thioredoxin with its binding partners, and thus inhibiting its 
activity in cells. This inhibition presumably causes the observed phenotype of rapid ferroptotic 
cell death. Given that thioredoxin is a key component of a major antioxidant system, it is 
possible that its modulation renders cells susceptible to oxidative stress that causes lipid 
peroxidation and other imbalances in cellular processes, eventually leading to ferroptosis; other 
thioredoxin inhibitors have not been reported to induce ferroptosis. 
To investigate this hypothesis, we assessed the cell phenotype upon genetic knockdown 
of thioredoxin. As shown in Figure 2.60 A,B, treatment of HCT 116 cells with siTXN, 
siGAPDH, and the scramble siRNA (siNeg) resulted in the generation of high levels of general 
ROS and lipid ROS only for the siTXN samples, supporting our previous hypothesis. The 
ferroptosis inhibitors (trolox, DFO, Fer-1) were unable to rescue cells from the siTXN-induced 
cell death potentially due to toxicity of these inhibitors (DFO), the long incubation time needed 
to genetically modulate the TXN gene in cells (72 hr), and the high levels of accumulated ROS 
(Fig. 2.60C). Furthermore, assessment of the combination of genetic knockdown of thioredoxin 
with ferroptocide resulted in sensitization of HCT 116 cells to compound treatment, leading to 
rapid cell death (50% cell death at 4 hr vs. 8 hr for siNeg control cells). Together, these data 
strongly suggest a direct effect of thioredoxin in ferroptocide-induced cell death (Fig. 2.61). 
In conclusion, these studies implicate thioredoxin in ferroptosis—a new target in the 
spectrum of ferroptotic cell death—yet detailed future experiments are needed to investigate the 








Figure 2.60. Genetic modulation of thioredoxin generates ROS. HCT 116 cells are treated for 72 hr with 
siRNA for thioredoxin, and the negative controls of GAPDH and scramble negative siRNA. (A) General ROS 
(B) lipid ROS were monitored via flow cytometry using carboxy-H2DCFDA and C11-BODIPY. (C) 
Monitoring the ability of ferroptosis inhibitors to rescue HCT 116 cells from cell death after 72 incubation of 
siTXN. (D) Western blot was used to assess the efficiency of the genetic knockdown for all three replicates. 
Data represent the mean ± s.e.m. are representative of n=3, biological triplicates. 
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Figure 2.62. Ferroptocide displays the best pharmacokinetic profile. C57BL/6 mice were treated with 
ferroptocide, P19, and P23 (40 mg/kg) via i.p. injection. Points: mean (n=3), bars: standard error 
 
2.10 Evaluation in vivo 
2.10.1 MTD and PK studies 
Given than ferroptocide demonstrated promising activity in cell culture, we set out to 
explore its activity in murine models. First, toxicity studies in C57BL/6 mice were conducted at 
single doses of 80 mg/kg and 100 mg/kg, which were concluded to be well-tolerated. Multiple-
Figure 2.61. Sensitization of siTXN cells to ferroptocide treatmnet. (A) HCT 116 cells were treated for 48 hr 
with siRNA for thioredoxin, and the scramble negative control. Time course was assessed at the indicated time 
points after treatment with 10 µM ferroptocide and raptinal (negative control). AV/PI via flow cytometry. (B) 
Western blot was used to assess the efficiency of the genetic knockdown for all three replicates. Data represent the 
mean ± s.e.m. and are representative of n=3, biological triplicates. 
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dose MTD was then established in the same model (3 mice/dose) given once daily (100 mg/kg) 
for 4 consecutive days. One mouse displayed signs of lethargy and thus was sacrificed on day 5. 
Upon establishment of a safe MTD (100 mg/kg), the pharmacokinetic (pK) profile of 
ferroptocide was assessed in C57BL/6 mice after intraperitoneal (i.p.) administration of 40 
mg/kg of compound. Comparing ferroptocide to its P19 and P23 analogues (Fig. 2.62), 
ferroptocide possessed the best pK profile with a 50 µM Cmax and half-life of 9.96 min. 







2.10.2 Efficacy model in 4T1 
To monitor the therapeutic relevance of ferroptocide, a subcutaneous murine model of 
4T1 triple negative breast cancer cells in female Balb/c mice was performed.  Potent activity of 





Half-life 9.96 min 
Cmax 50 µM 
Figure 2.63. Compound inhibits 4T1 tumor growth in vivo as measured by tumor volume (A) and tumor mass 
(B) after tumor excision on day 21. Balb/c mice were administered with 50 mg/kg ferroptocide or vehicle. * 0.01 
≤ p < 0.05, ** p < 0.01 relative to vehicle treatment. 
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tumor establishment, mice were dosed with 50 mg/kg for 5 doses and were consistently 
monitored for changes in tumor size and signs of toxicity. As shown in Fig. 2.63, treatment with 
ferroptocide retarded tumor growth compared to vehicle control in a statistically significant 
manner. In addition, there were no signs of toxicity after this dosing regimen.  
2.10.3 Activity in immunocompetent and immunocompromised mice 
The non-apoptotic nature of ferroptocide inspired exploration of its ability to modulate 
the immune system. Compounds that induce non-apoptotic mode of cell death are attractive 
anticancer agents, as they could potentially elicit an immune response.100 We investigated the 
role of the immune system by assessing the efficacy of ferroptocide in a subcutaneous murine 
model of 4T1 triple negative breast cancer cells in immunocompetent (Balb/c) compared to 
immunocompromised (SCID) mice.  Upon tumor establishment, mice were dosed with 50 mg/kg 
(twice a week) for five doses before being sacrificed (Fig. 2.63). Measurements of tumor volume 
indicated a 40% tumor growth retardation in compound-treated Balb/c mice compared to 
vehicle-treated animals. As shown in Figure 2.64, there was no effect of ferroptocide in 
immunocompromised mice suggesting that T and B cells play a critical role in the activity of 
ferroptocide in vivo. The potency of ferroptocide in this in vivo model is likely limited by poor 







Figure 2.64. Ferroptocide retards tumor growth in immunocompetent mice. Ferroptocide inhibits 
subcutaneous 4T1 tumor growth in immunocompetent Balb/c mice (A) but not in immunodeficient SCID 
mice (B) as measured by tumor volume. Ferroptocide was administered intraperitoneally at 50 mg/kg, 
twice a week, five doses (n=7 mice per group). Data represent the mean ± s.e.m. p values are relative to 





In this chapter, I have highlighted the motivation, discovery, mechanistic and target 
identification/validation efforts of a novel tool compound named ferroptocide. A series of 
experiments suggested that ferroptocide induces non-apoptotic cell death, which was elucidated 
to be ferroptosis. Ferroptosis is a newly coined mode of cell death (2012) that has been the focus 
of many research groups. As described in chapter one, the current landscape of ferroptosis 
activators can be categorized in two classes including class I: compounds that inhibit system XC
- 
and deplete glutathione levels in cells (erastin, sorafenib), and class II: compounds that inactivate 
GPX4, directly via covalent inhibition (RSL3), or indirectly via degradation (FIN56). 
Ferroptocide is distinct from these published probes as it targets a new target, thioredoxin, in an 
entirely different antioxidant system in cells.  
Excitingly, genetic modulation of thioredoxin in cells caused a similar death profile to 
that of ferroptocide. Combination studies of genetic knockdown of thioredoxin in colon cancer 
cells followed by treatment with ferroptocide resulted in an increase in sensitization of these 
cells to compound treatment suggesting a role of thioredoxin in ferroptocide-mediated cell death. 
The data described herein implicate thioredoxin as a novel target in ferroptosis and call for more 
in-depth studies to elucidate the direct link between ferroptosis and thioredoxin antioxidant 
system.  
Discovery of ferroptocide is important as it provides a new ferroptotic probe with broad 
utility regardless of the cell line type. The main issues with the gold standard compounds that are 
used to study ferroptosis (erastin and RSL3) reside in their limited bioactivity limited to specific 
cell systems and lack of quantitative cell death. Ferroptocide cause quantitative and rapid 
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ferroptotic death, making it invaluable in the chemical biologist toolbox, as it can uravel new 
mechanistic insights about ferroptosis in cells and in animal models.  
Furthermore, given that ferroptosis is a non-apoptotic mode of cell death, it would be of 
interest to explore if ferroptotic compounds can activate the immune system via the release of 
DAMP signals. We were able to perform limited experiments to this end, where we discovered 
that the activity of ferroptocide is dependent upon the presence of the immune system. 
Additional studies are needed to investigate the nature of compound interaction with the immune 
system, as it can offer insights for use of pro-ferroptotic compounds as a new anticancer strategy 


















































































Supplementary Figure 2.3. Coomassie stain corresponding to fluorescence gel in Fig. 2.58 A,B respectively. 




Supplementary Figure 2.4. Coomassie stain corresponding to fluorescence gels in Fig 2.59B. 
 
 
Supplementary Table 2.1. Top 30 Upregulated genes after ferroptocide treatment of HT-29 cells (RNA-seq)  






Supplementary Table 2.2. Top 25 downregulated genes in HT-29 cells after ferroptocide treatment 
FDR: false discovery rate 
 
 
2.13 Materials and methods 
Cell culture and reagents: Cells were grown at 37 °C under a humidified 5% 
CO2 atmosphere, in a culture medium consisting of high-glucose (Life Technology) DMEM 
media for Mia PaCa-2, D54, U87, K7-M2, SK-MEL-5, and 3LL cells or RPMI for ES-2, HCT 
116, MDA-MB-231, A549, T47D, B16-F10, and BT-549 cells or McCoy’s 5A media for 
HT29 cells. All media were supplemented with 10% FBS (Gemini), penicillin (50 IU/ml), 
streptomycin (50 μg/ml) and glutamine (2 mM) (Cellgro). Primary cells were isolated from 
pleural effusions of metastatic patients at Carle Foundation Hospital (IRB #15149) following 
a protocol as described previously.101  
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Anticancer screen: 40 µL of media was added to each well of a 384-well tissue culture-treated 
plate. 3x100 nL of compound in DMSO was then pin-transferred from compound storage plates 
(2 mM stocks) into media-containing wells using the Platemate Plus at the UIUC High 
Throughput Screening Facility. A 100,000 cells/mL suspension of ES-2 cells was prepared, and 
10 µL was added to each well for a final concentration of 1000 cells/well. Doxorubicin (100 µM 
final) was used as a positive control. Plates were sealed with gas-permeable seals and incubated 
at 37 °C for 72 h. After incubation, 5 µL of Alamar blue (440 µM resazurin in sterile PBS) was 
added and allowed to incubate for 3-4 h, until visible color change occurred. Fluorescence was 
measured in a Molecular Devices SpectraMax 3 (Ex = 555 nm, emission = 585 nm, emission 
cutoff = 570 nm).  
Dose response (IC50) curves: To a 384-well plate, 40 µL of 1.25X compound dilution or 1.25% 
DMSO-containing media was added (final volume of 1% DMSO). Concentrations of compounds 
tested were 100 µM to 100 nM. On each plate at least 3 technical replicates were performed. 
Next, 10 µL of a 100,000 cells/mL suspension was added to each well, yielding a final 
concentration of 1,000 cells/well. To three wells in column 2 was added 1 µL of 10 mM 
doxorubicin (final concentration of 200 µM) as positive control of cell death. Plates were sealed 
with gas-permeable seals and incubated at 37 ˚C for 72 h. At that time, 5 µL of Alamar blue (440 
µM resazurin in sterile PBS) was added and plates were incubated for 3-4 hours. Fluorescence 
was read on a Molecular Devices SpectraMax 3 (excitation = 555 nm, emission = 585 nm, 
emission cutoff = 570 nm). Wells were normalized to the average of untreated wells (0% cell 
death). The data were plotted as compound concentration versus percent dead cells and fitted to a 
logistic-dose response curve using OriginPro 2015 (OriginLab, Northampton, MA). The data 
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were generated in triplicate, and IC50 values are reported as the average of three separate 
experiments with standard error of the mean. 
 
Hemolysis assay: Whole human blood in citrate phosphate dextrose was obtained from 
Bioreclamation LLC, stored at 4 ˚C and used before expiration date. 100 µL of whole blood was 
combined with 500 µL saline (0.9% NaCl) and centrifuged for 5 min at 300xg. The supernatant 
was carefully removed from the erythrocyte pellet and the liquid was discarded. Washed pellet 
3x in 500 µL saline. The erythrocyte pellet was resuspended in 800 µL of Red Blood Cell Buffer 
(10 mM Na2HPO4, 150 mM NaCl, 1 mM MgCl2, pH 7.4). To a 0.5 mL eppendorf tube or a PCR 
plate was added 1.0 µL of 30X compound in DMSO and 19 µL RBC Buffer.  For negative 
controls, 1.0 µL DMSO was combined with 19 µL RBC buffer. For positive controls, either 20 
µL MilliQ H2O or 1.0 µL 30% Triton X-100 were combined with 19 µL RBC Buffer. Tubes or 
plates were briefly centrifuged. Next, 10 µL of washed erythrocyte suspension was added to each 
tube, then sealed. After incubation at 37 ˚C for 2 h, samples were centrifuged for 5 min at 300xg, 
and 20 µL of supernatant was carefully removed and transferred to wells of a clear flat-bottomed 
384-well plate. Absorbance was measured at 540 nm. The data were plotted as compound 
concentration versus percent hemolysis, and fitted to OriginPro (OriginLab, Northampton, MA). 
 
Western botting. ES-2 and HCT 116 cells were treated with compound for the appropriate 
amount of time. Cells were harvested by centrifugation (3 min, 500xg), washed with PBS and 
resuspended in RIPA lysis buffer (50 mM Tris, 150 mM NaCl, 1% Triton X-100, 0.5% Na-
deoxycholate, 0.1% SDS, pH = 7.4) containing 1X protease inhibitor cocktail, and 1 mM PMSF 
on ice. Whole cell lysates were normalized after determining their protein concentration using a 
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Bradford assay. Samples were resolved in a 4–20% gradient SDS-PAGE gel (Bio-Rad) at 120 V 
for 1 h, and then transferred to an activated PVDF membrane in Towbin transfer buffer (192 mM 
glycine, 25 mM Tris-HCl, 20% methanol, pH = 8.3) for 2 h at 45 V. Membranes were blocked 
overnight at 4 ˚C in 5% milk or bovine serum albumin in TBST (as per primary antibody 
manufacturer’s instruction). Membranes were blotted for molecules of interest with primary 
antibody (1:1000 in 5% BSA in TBST) overnight at 4 ºC. The bound primary antibodies were 
detected after using the appropriate secondary HRP conjugated antibodies (1:5000 in TBST) for 
1 hour at room temperature. The immunoblots were incubated for 3 min in SuperSignal West 
Pico Chemiluminescent Substrate (ThermoFisher) mixture before visualization in a 
ChemiDocTM Touch Imaging System (Bio-Rad) and processed using ImageLab software (Bio-
Rad). Antibodies used: Thioredoxin (Cell Signaling #2429), KEAP-1 (Cell Signaling #8047), 
GSTO1 (Abcam #129106), Beta-Actin (Cell Signaling #5125), Anti-rabbit IgG HRP linked (Cell 
Signaling #7074) GAPDH (Cell Signaling #2118), PARP-1 (Cell Signaling # 9532). 
 
Cell viability via flow cytometry:  ES-2, HCT 116, Mia PaCa-2, A549, and 4T1 cells (1 x 105 
cells/mL) were plated overnight in 12 well plates, prior to addition of compounds. For protection 
studies, samples were pre-treated with each protecting agent such as 25 µM Q-VD-OPh, 250 µM 
trolox, 2 µM ferrostatin-1, 5 mM NAC-1 (neutralized pH), or 100 µM deferoxamine (DFO) for 
two hours or 1 hr (NAC-1) before compound addition. Cells were incubated for the appropriate 
times and harvested for flow cytometry analysis. Cell pellets were resuspended in binding buffer 
(10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) containing 2 µg/mL propidium iodide 
and 5 µL/mL Annexin V-FITC conjugate antibody and analyzed for cell viability after gating for 
forward and side scattering. Ten thousand events were collected per sample in BD LSR II Flow 
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Cytometer (BD Bioscience) and FCS express V6, De Novo software was used to perform 
experimental analysis.  
 
Confocal microscopy: ES-2 cells (3 x 105 cell) were attached overnight in 1.5 mm petri dish 
plates containing 2 ml of RPMI media. Prior to imaging, cells were stained for 30 min with 
Mitotracker Red CMXRoss at 100 nM final concentration. Upon media replacement, samples 
were treated with 10 µM P30 or 1 µM BODIPY azide for 30 min followed by a PBS wash. PBS 
or phenol free media was added to each dish and cells were stained with Hoechst 33342 (1µg/ 
mL). Samples were visualized and analyzed using Carl Zeiss LSM 700. 
 
Confocal microscopy competition studies: ES-2 cells (3 x 105 cell) were attached overnight in 
1.5 mm petri dish plates containing 2 ml of RPMI media. Prior to imaging, cells were stained for 
30 min with Mitotracker Red CMXRoss at 100 nM final concentration. Upon media 
replacement, samples were pretreated with 3x IC50 of ferroptocide, P27, L1, QQ1 for 30 min 
followed by treatment with 5 µM P30 for an additional 30 min and a PBS wash. PBS or phenol 
free media was added to each dish and cells were stained with Hoechst 33342 (1µg/ mL). 
Samples were visualized and analyzed using Carl Zeiss LSM 700. 
 
Transmission electron microscopy (TEM): ES-2 cells (2 x 105 cells/mL) were plated overnight 
in a 6-well plate. Compounds stocks were loaded in DMSO (0.05% final volume), and cells were 
incubated for 30 min. Following incubation, cells were pelleted at 500xg, for 3 min, and washed 
with Hank’s buffered salt solution (HBSS). Karnovsky’s fixative (0.5 mL) was added to cell 
pellets upon gently mixing and span at 500 xg, 3 min. Samples were stored at 4°C till analysis. 
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Preparation and imaging of samples was performed by the Center for Microanalysis of Materials 
of the Frederick Seitz Materials Research Laboratory Central Facilities, University of Illinois. 
Images of several cells in each sample were taken; displayed images are representative images. 
 
Measurement of cellular ROS production: ES-2 and HCT 116 cells (3 x 105 cells/mL) were 
plated in 6-well plates. Cells were treated with DMSO, ferroptocide at the indicated 
concentrations, Etoposide (100 µM), TBHP (100 µM) for 1hr and 1.5 hr respectively. Cells were 
washed with HBSS and incubated in the dark for 25 min with 25 µM carboxy-H2DCFDA probe. 
Cells were then washed 3x with HBSS and harvested at 1000xg, 3 min. After resuspension in 
500 µl HBSS buffer, samples were subjected to flow cytometry to record ten thousand events per 
sample in FL1 channel in BD LSR II Flow Cytometer (BD Bioscience). FCS express V6 De 
Novo software was used to generate the histograms. 
 
Measurement of cellular lipid ROS production: ES-2, HCT 116, and 4T1 cells (1 x 105 
cells/mL) were plated in 12-well plates. Cells were pretreated for 2 hr with 100 µM 
deferoxamine followed by treatment with DMSO, 10 µM ferroptocide, 10 µM RSL3, or 100 
µM TBHP for 1hr, 1.5 hr and 2,4,6 hr respectively. Cells were washed with HBSS and incubated 
in the dark for 20 min with 5 µM C11-BODIPY probe. Cells were then washed 2x with HBSS 
and harvested at 1000xg, 3 min. After resuspension in 500 µl HBSS buffer, samples were 
analyzed with flow cytometry to record ten thousand events per sample in FL1 channel in BD 





Measurement of mitochondrial ROS production: ES-2 cells (1 x 105 cells/mL) were plated in 
12-well plates and allowed to attach overnight. Cells were treated for 1 hr with DMSO, 10 and 
25 µM ferroptocide, 5 µM IB-DNQ, and 10 µM rotenone. Cells were washed with HBSS and 
incubated in the dark for 10 min with 5 µM MitoSOX Red probe. Cells were then washed 2x 
with HBSS and harvested at 1000xg, 3 min. After resuspension in 500 µl HBSS buffer, samples 
were analyzed with flow cytometry to record ten thousand events per sample in PE channel in 
BD LSR II Flow Cytometer (BD Bioscience). FCS express V6 De Novo software was used to 
generate the histogram. 
 
GPX4 LC-MS based activity assay: 1 million ES-2 cells/ well, 6 well plate were allowed to 
attach overnight and then treated with DMSO, 10 μM of each compound: ferroptocide, raptinal, 
and RSL3 for 1 hr. GPX4 enzymatic activity assay was performed with a GPX4 specific 
substrate, phosphatidyl choline hydroperoxide (PC-OOH) as described previously with minor 
modifications.64 PCOOH was prepared as reported by Roveri and coworkers but using soybean 
lipoxidase type I-B (L7395, Milipore Sigma).102 Cells were washed with PBS and lysed by liquid 
nitrogen freeze-thaw method in the assay buffer (137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 
2 mM KH2PO4, 1mM EDTA, 0.1 mM DFO; pH 7.4). Cell lysates were cleared by centrifugation 
at 14,000 rpm for 10 min at 4°C. Bradford assay was used to determine protein concentration; 
200 μg of protein or assay buffer (PCOOH control sample) was mixed with 10 µL PC-OOH in 
methanol, 5mM reduced glutathione, and assay buffer to a final reaction volume of 500 µL. The 
reaction mixture was incubated at 37°C for 15 mins and extracted with 250 µL 
chloroform:methanol (2:1) solution. The lipid extract was evaporated under nitrogen and re-




In vitro glutathione assay: To an eppendorf tube added, 245 µL of 1X PBS, 5 µL of 10 mM 
DMSO stock of ferroptocide or P23, 250 µL of reduced GSH (5mM final concentration). 
Reactions were vortexed briefly and incubated at 37°C. Adduct formation was monitored at the 
indicated time points (0, 0.5, 1, 2, 3, 24 hr) by mixing an aliquot of 50 µL from the reaction 
mixture with 50 µL of MeOH before LC/MS analysis.  
 
Cell Fractionation: Cells (ES-2, HCT 116) were grown to confluency in a T-25 flask (7 million 
cells), collected by centrifugation and washed with PBS. Cell fractionation was performed as 
instructed in the Cell Signaling Cell Fractionation kit (9038S).  
Isolation of Mitochondria: Cells (ES-2, HCT 116) were grown to confluency in a T-75 flask 
(20 million cells), collected by centrifugation, and washed with PBS. Mitochondria were isolated 
using the ThermoScientific Mitochondria Isolation kit (#89874) as instructed. 
 
Cell cycle studies: Cells (500k/ well, 12 well) were grown to confluency and treated with 
compound at the indicated concentrations. Samples were collected by centrifugation and washed 
with PBS. After aspirating off the media, cells were fixed with cold 70% ethanol (1mL) and 
saved at 4°C. Samples were span at 1700g, 7 min, washed with PBS, and incubated for 1 hr at r.t. 
with 50 µL of RNAse (1mg/ml). After addition of 300 µl of PI (50 µg/mL), samples were 





ɣH2AX studies: Cells (200k/ well, 12 well) were treated with compounds at the indicated 
concentrations, fixed and permeabilized with 70% ethanol at 4°C. Samples were washed 2x with 
cell staining buffer (Biolegend, #420201) and PBS 1x. Upon addition of ɣ-H2AX-FITC at 1:20 
ratio (Biolegend, #613403) in 500 µl of cell staining buffer for 1 hr at 4 degrees, samples were 
washed with PBS and treated with 300 µl of PI (50 µg/mL). Samples were analyzed via flow. 
 
Antibody pulldown studies: 1 million cells (ES-2, HCT 116) were treated with compound (1 
µM) for 30 min. Cells were lysed with 0.5% CHAPS in HEPES (with protease inhibitor) buffer 
and protein concentration was determined via Bradford assay. Dynobead magnetic beads 
(Thermofisher #11203D, activated per manufacturer’s instructions) were incubated with 1 µl of 
BODIPY (Thermofisher #A-5770) or ETFA (Abcam #ab126131) antibody for 48 hr at 4°C in 
immunoprecipitation buffer (20 mM Tris, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 5% glycerol, 
pH=7.5). 100 µg of protein were added to beads after 2x wash and incubated 48–72 hr in a 
shaker at 4°C. After incubation, supernatant was saved, beads were washed with buffer, and 
eluted with SDS laemmli dye. Samples were denatured at 95°C, 5 min and loaded without beads 
(15 µl) in a 4–20% gel. In-gel fluorescence labeling was monitored before and after the 
pulldown. 
 
CETSA studies: Cells (ES-2, HCT 116) were grown to confluency (300k cells/tube), treated 
with DMSO or ferroptocide (20 µM) for 30 min, collected by centrifugation, and washed with 
PBS. CETSA protocol was followed as described by Molina and coworkers.103 Briefly, upon 
addition of 40 µl of PBS containing protease inhibitor, samples were heated at the indicated temp 
for 3 min and cooled off at room temp. for another 3 min. Lysing was performed via liqiuid 
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nitrogen flash-freezing method (3x), and soluble fraction was isolated after centrifugation at max 
speed for 20 min at 4°C. (Note: cell pellets can be saved at -80°C overnight after freezing with 
liquid nitrogen). Upon removal of 20 µl of each sample and addition of 5 µl of laemmli dye, 
samples were denatured at 70 °C for 10 min. Samples were then loaded in a 12% gel and 
subjected to western blot analysis as described here. ETFA antibody (1:3000) for >12 hr at 4 °C.  
 
In-gel fluorescence. HCT 116 cells (3 x 105 cells/mL) were treated with DMSO or 20 µM 
ferroptocide for 30 min followed by 30 min treatment with 1 µM P30 in 6-well plates (final 
DMSO concentration of 0.5%). Cells were harvested by centrifugation (500xg, 3 min), washed 
with PBS, and resuspended in RIPA lysis buffer (50 mM Tris, 150 mM NaCl, 1% Triton X-100, 
0.5% Na-deoxycholate, 0.1% SDS, pH = 7.4) containing 1X protease inhibitor cocktail on ice. 
Protein concentration was determined by the Bradford assay and lysates were stored at -20 ˚C 
until further use. Samples were resolved in a 4–20% SDS-PAGE gel (Bio-Rad) at 120 V for 70 
min. After PBS washes, each gel was scanned for fluorescence signal using a Molecular 
Dynamics Typhoon 9400 Multilaser Scanner at the Proteomics Center at UIUC (excitation at 
526 nm, green laser, high sensitivity, 530 pmt). Gels were then treated with Coomassie Blue 
stain (Imperial Stain, ThermoFisher) via shaking for 45 min to stain for total protein content. 
Upon proteome labeling, gels were destained for 15 min–overnight on MilliQ H2O followed by 
imaging in a Gel Dox XR+ from Bio-Rad (ex. 470 nm, UV High filter). 
 
Biotin-streptavidin pulldown for target ID78: ES-2 and HCT 116 (20 x 106 cells/flask) were 
plated in T175 flasks and treated with DMSO or 20 μM ferroptocide for 1 hr followed by 
treatment with 20 μM P29 for 1 hr. Cells were lysed via sonication (6500g, 4 min) in DPBS and 
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the soluble proteome was isolated after ultrasonication (45000g, 45 min). Bradford assay was 
used to determine protein concentration. The soluble protein lysates in DPBS (pH 7.4) (500 μL, 
2 mg/mL) were treated with biotin-azide (100 μM, 50X stock in DMSO), TCEP (1 mM, 50X 
fresh stock in water), TBTA ligand (100 μM, 17X stock in DMSO:t-butanol = 1:4), and 
copper(II) sulfate (1 mM, 50X stock in water) followed by incubation at r.t. for 1 hr. Samples 
were centrifuged (6500 g, 4 min, 4 °C) and the supernatant was discarded. The pellets were 
resuspended in cold methanol by sonication (2x) and then were solubilized in DPBS containing 
1.2% SDS via sonication and heating (90 °C, 5 min). A final SDS concentration of 0.2% was 
achieved after addition of 5 mL of DPBS to the SDS-solubilized proteome samples. The solution 
was incubated overnight at 4 °C with 100 μL of streptavidin-agarose beads (ThermoFisher, 
washed 3X with DPBS to remove storage buffer). Samples were rotated at 22 °C for 2 hr before 
being washed by 5 mL 0.2 % SDS/DPBS, 3 X 5 mL DPBS, and 3 X 5 mL water. The beads were 
pelleted by centrifugation (1400 X g, 3 min) between washes.  
On Bead trypsin digestion  
The washed beads were suspended in 500 µL of 6 M urea/DPBS and 10 mM DTT (from 20X 
stock in water) and heated for 20 min on a 65 °C heat block. Upon addition of iodoacetamide (20 
mM from 50X stock in water), samples were allowed to react at 37 °C for 30 min while shaking. 
Following reduction and alkylation, the beads were pelleted by centrifugation and resuspended in 
200 μL of 2 M urea/DPBS, 1 mM CaCl2 (100X stock in water), and sequencing-grade trypsin (2 
μg). The bead digestion occured overnight at 37 °C while shaking. Next day, the beads were 
pelleted by centrifugation and washed with 2 X 50 μL water. The washes were combined with 
the supernatant from the trypsin digestion step, and after addition of formic acid (15 μL) to each 
sample, they were stored at -20 °C until mass spectrometry analysis.  
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Liquid Chromatography- Mass spectrometry Analysis 
LC/LC-MS/MS analysis was performed on an LTQ-Orbitrap Discovery mass spectrometer 
(ThermoFisher) coupled to an Agilent 1200 series HPLC. Peptide digests were pressure loaded 
onto a 250 μm fused silica desalting column packed with 4 cm of Aqua C18 reverse phase resin 
(Phenomenex). The peptides were eluted onto a biphasic column (100 μm fused silica with a 5 μ, 
tip, packed with 10 cm C18 and 4 cm Partisphere strong cation exchange resin (SCX, Whatman) 
using a gradient 5-100% Buffer B in Buffer A (Buffer A: 95% water, 5% acetonitrile, 0.1% 
formic acid; Buffer B: 20% water, 80% acetonitrile, 0.1% formic acid). The peptides were then 
eluted from the SCX onto the C18 resin and into the mass spectrometer using 4 salt steps 
previously described.104
 
The flow rate through the column was set to ~0.25 μL/min and the spray 
voltage was set to 2.75 kV. One full MS scan (FTMS) (400-1800 MW) was followed by 8 data 
dependent scans (ITMS) of the nth most intense ions. The tandem MS data were searched using 
the SEQUEST algorithm using a concatenated target/decoy variant of the human UniProt 
database. A static modification of +57.02146 on cysteine was specified to account for alkylation 
by iodoacetamide. MS2 spectra matches were assembled into protein identifications and filtered 
using DTASelect2.0 to generate a list of protein hits with a peptide false-discovery rate of 5%. 
Generation of CRISPR-mediated knockout HCT 116 cell lines:  
TXNRD3, TXNRD2, TXNRD1, PTGES2, PGLS, PDP1 KO cell lines were generated using 
CRISPR Cas9 nature protocol.105 In brief, sgRNAs targeting TXNRD3, TXNRD2, TXNRD1, 
PTGES2, PGLS, PDP1, and TXN (described in table below) were designed, amplified, and 
cloned into P2-gRNA (from Perez lab) in a one-pot reaction as described previously.106 Plasmid 
DNA was isolated using the QIAminiprep kit (QIAGEN cat # 27104) according to 
manufacturer’s recommendation. HCT 116 cells (3 x105 cells/ mL) were transfected for 48 hr 
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with specific plasmids (gene of interest [GOI] sgRNA, empty vector GFP, TV puro, TV hygro, 
Cas9, pAB059) using lipofectamine transfection agent following manufactures protocol. After 7-
10 days of puromycin and hygromycin double selection, clonal cells were isolated, expanded and 
analyzed for KO efficiency of GOI using a three-way PCR as described previously107 using GOI 
fwd primer, GOI rev primer, and GFP rev primer ww443. Desired clonal cells were used for 
downstream analysis as described in the in-gel fluorescence experiment above.  
Supplementary Table 2.3. Sequences of sgRNAs used for generation of isogenic cell lines. 
sgRNA Sequence 
TXNRD3 Fwd CACCGACACTCAATCGTGCCCTCAC 
TXNRD3 Rev AAACGTGAGGGCACGATTGAGTGTC 
TXNRD2 Fwd CACCGATTAGGAGGGCGCTTCCGG 
TXNRD2 Rev AAACCCGGAAGCGCCCTCCTAATC 
TXNRD1 Fwd CACCGAGAACGGCGATGGCCGCCGT 
TXNRD1 Rev AAACACGGCGGCCATCGCCGTTCTC 
PTGES2 Fwd CACCGCGCCGTGTGGTACAGCCCC 
PTGES2 Rev AAACGGGGCTGTACCACACGGCGC 
PGLS Fwd CACCGCGTGCTCTCGGCGTGATCGA 
PGLS Rev AAACTCGATCACGCCGAGAGCACGC 
PDP1 Fwd CACCGAACGATTCTTCCCGACGAGG 
PDP1 Rev AA CCCTCGTCGGGAAGAATCGTT C 
TXN Fwd CACCGTACTTCAAGGAATATCACGT 










Supplementary Table 2.4. Sequences of primers used for generation of isogenic cell lines. 
Primer Sequence 
TXNRD3 Fwd TCA GAT TGC AGC GGG ATG TT 
TXNRD3 Rev GCT GTT AAA AAC CGG CCT CC 
TXNRD2 Fwd CCT ATC CCA GTG TTC CAC CC 
TXNRD2 Rev GAG ACC ACA GGT GCA GTC AG 
TXNRD1 Fwd TGG CCT GTG GGA CTT AAA TGG 
TXNRD1 Rev CGA GTA GCT GCG ACT ACA GG 
PTGES2 Fwd CTG CAG CTC GTA AGG GGA G 
PTGES2 Rev GGG GTG AGC CTA TAG TCC CA 
PGLS Fwd TTC TCG AGT TCC CAG GAG CT 
PGLS Rev TTG GCA TGA TAC CCA GTG GC 
PDP1 exon 3 Fwd CTC CCC TCC CAC TCG TCA 
PDP1 exon 3 Rev CCT CCC TGG AGC TCA CTC T 
TXN Fwd CCC ACA TTG AAA CAT GGG CC 
TXN Rev TGG TGA CTC CAT CAA GCC TAT G 
ww443 GFP rev TGCCCTTGTCTTGTAGTTTCC 
Ab299 PuroR1 CCTGACTGTGGGCTTGTAT 
Ab297 HygroR1 GCGGTGAGTTCAGGCTTTTT 
T7 Primer TAATACGACTCACTATAGGG 
 
siRNA transfection: HCT 116 cells (1 x 105 cells/mL) were transfected for 72 hr with 5 nM of 
GSTO1 (silencer select #s18089, ThermoFisher), KEAP1 (silencer select #s18981 
ThermoFisher), GAPDH as positive control (silencer select #4390849, ThermoFisher) or 
negative control siRNA (Qiagen, #1027280) following the Interferin polyplus transfection 
protocol. Cells were then pretreated for 30 min with DMSO or 20 μM ferroptocide followed by 
30 min treatment with 1 μM P30. Cells were harvested, washed and subjected to in gel-
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fluorescence studies as described above. siRNA transfection efficiency was assessed via western 
blot analysis.  
 
Studies with siRNA transfection of thioredoxin: HCT 116 cells (1 x 105 cells/mL) were 
transfected for 72 hr or 48 hr with 5 nM of TXN (silencer select #s1 4390824, ThermoFisher), 
GAPDH as positive control (silencer select #4390849, ThermoFisher) or negative control siRNA 
(Qiagen, #1027280) following the Interferin polyplus transfection protocol. Cells were then used 
to monitor general and lipid ROS accumulation or time course cell viability studies respectively 
using flow cytometry as described in this manuscript. In the time course studies, cells were 
treated with DMSO, 10 μM ferroptocide, 10 μM raptinal at the indicated time points, followed 
by AV/PI analysis.  
In the case of protection studies, same transfection protocol was followed (72 hr, 5nM siTXN, 
siGAPDH, siNegative) after pretreatment of HCT 116 cells with 250 µM trolox, 100 µM 
deferoxamine (DFO), or 2 µM ferrostatin-1 for two hours. siRNA transfection efficiency for all 
experiments was assessed via western blot analysis.     
 
Thioredoxin validation via pulldown: HCT 116 cells (1 x 106 cells/flask) in T25 flasks were 
treated with DMSO or 20 μM ferroptocide for 30 min followed by a 60 min treatment with 20 
μM P29. Cells were lysed via sonication in PBS and the soluble proteome (100 µg) was 
subjected to click reactions with 400 µM biotin-azide, 1 mM TCEP freshly made, 100 µM 
THPTA, 1 mM CuSO4 at r.t. for 60 min. Samples were quenched with 70% cold ethanol, 
centrifuged at 6500xg, 4 min and supernatant was discarded. The pellets were solubilized in 
1.2% SDS/PBS solution by heating (90 °C, 5 min). Pierce streptavidin magnetic beads (50 µL) 
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were activated per manufacturer’s recommendation and added to each sample in addition to 500 
µL of PBS to achieve a final 0.2% SDS concentration. After rotating for 12 hr at 4 °C, proteins 
of interest were eluted with 2x SDS laemmli dye. Proteins were resolved in 4-20% gradient SDS 
gel (120V, 60 min), transferred in activated immunoblot membranes, blocked in 5% BSA TBS-
T, and incubated overnight with thioredoxin antibody (1:1000). Membranes labeled with the 
primary antibody thioredoxin (Cell Signaling # 229) and Beta-actin (Cell Signaling #5125) 
were then incubated with anti-rabbit HRP-conjugated antibody (Cell signaling #7074) diluted 
1:3,000 for 60 min and washed with TBS-T for 2x10 min. Membranes were visualized using 
the Pico Plus Chemiluminescence Kit (#3477 ThermoFisher); images were captured using a 
ChemiDocTM Touch Imaging System (Bio-Rad) and processed using ImageLab software (Bio-
Rad).  
 
TXNGFP and TXNGFP mutants in-gel fluorescence: HCT 116 cells (3 x 105 cells/mL) at 
80% confluency in 6 well plates, were transfected with 2.5 µg TXNGFP, empty vector GFP, or 
cysteine to serine mutant plasmid DNA for 24 hr (jetPRIME, Polyplus). Cells were then 
pretreated with DMSO or 20 µM ferroptocide followed by treatment with 20 µM P29 for 1 hr. 
50 µg of cell lysate was subjected to click conditions (freshly made 1mM TCEP, 100 µM 
THPTA, 1 mM CuSO4) using 20 µM Cy3 azide fluorophore at r.t. for 1 hr. Reaction was stopped 
with 50 µL 2x SDS and proteins were resolve at 120 V for 1 hr. After a PBS wash, each gel was 
scanned for a fluorescence signal using a Molecular Dynamics Typhoon 9400 Multi-laser 





Site-directed mutagenesis: New England Biolabs (NEB) Q5 Site-directed mutagenesis kit 
protocol (#E0554) was used to generate cysteine to serine mutants for each of the five cysteines 
of thioredoxin in NEB highly efficient chemically competent cells by employing the primers 
shown below. Plasmid DNA was isolated using the QIAminiprep kit (QIAGEN cat # 27104), 
submitted for sequencing at Roy J. Carver Biotechnology center, and found to contain only the 
desired mutant. HCT 116 cells (3 x 105 cells/mL) were platted in 6 well plates. Upon reaching 
80% confluency, cells were transfected for 24 hr with 1 µg plasmid DNA of each mutant or 
empty GFP vector. Next day, cells were treated with DMSO or 20 µM ferroptocide for 30 min, 
followed by 60 min treatment with 20 µM P29. Cells were harvested, washed 2x with PBS and 
lysed in RIPA buffer. Samples (50 µg) were then subjected to click chemistry conditions with 
Cy3-azide and in-gel fluorescence studies as described above. 
 














Thioredoxin activity assay: HCT 116 cells (1 x 106 cells/flask) were treated with DMSO, 10 
µM P18, 50 µM PMX464, or 50 µM PX-12 for 30 min. Cells were harvested by centrifugation, 
resuspended in the assay buffer and lysed via sonication. For each condition, 20 µg of cell lysate 
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was used to measure the activity thioredoxin activity following manufacturer’ protocol (Cayman 
Chemical, Fluorescent Thioredoxin Activity Assay kit # 20039) in a 96-well black-walled plate. 
For in vitro studies, human thioredoxin (10 μL of 0.2 μM solution) was used in addition to 
thioredoxin reductase (10 μL of 1.0 μM solution), 1 µl of DMSO, ferroptocide, PMX44, or PX-
12 at indicated concentrations, 5 μL of NADPH (diluted according to manufacturer’s 
instructions), and assay buffer to a final volume of 75 µL. The plate was incubated at 37 °C for 
30 min followed by immediate addition of 20 µL fluorescent substrate per each well (diluted as 
instructed in the kit). Fluorescence was then monitored over 1 hr at 520 nm after excitation at 
480nm in a SpectraMax M3 (Molecular Devices) instrument at 37 °C.  
 
RNA sequencing: Total RNA was extracted by RNeasy Kit (QIAGEN) and digested with 
DNase (QIAGEN) from n=3 samples per condition (DMSO, 10 µM ferroptocide cells treated 
for 6 hr). RNA quality was assessed with a 2100 Agilent Bioanalyzer prior to library preparation. 
The RNAseq libraries were prepared using the TruSeq Stranded mRNAseq Sample Prep kit 
(version 1) following manufacturer’s instruction (Illumina). Libraries were then quantified, 
pooled, and sequenced by single-end 150 base pairs using the Illumina HiSeq 4000 platform at 
the Roy J. Carver Biotechnology center. FASTQ files were generated and demultiplexed with the 
bcl2FASTQ v2.17.1.14 Conversion Software (Illumina). Libraries were sequenced at an average 
depth of 40-50 million reads per sample. The spliced read aligner Salmon (v0.8.2) was used to 
align sequencing reads to NCBI’s GRCh38.p11 transcriptome. Counts were summarized to the 
gene level (Annotation release 108) using tximport (v 1.6.0) and the “lengthScaledTPM” 
method. The counts were normalized using the TMM method from edgeR (v 3.20.5) and then 
transformed to log2 counts per million (logCPM) with prior.count = 3. TMM normalization was 
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re-done after filtering and then limma’s (v 3.34.5) voom method was used to find differentially 
expressed genes for the pairwise comparisons of treatment vs. control in two different cell lines 
(A549 and HT-29), and the interaction between treatment and cell lines. False discovery rate 
adjustment was performed for multiple hypothesis testing with the Benjamini-Hochberg method. 
Gene-level read counts were obtained based on ESGEA (v 1.6.1) gene annotation for the Gene 
Ontology BP, CC, and KEGG pathway.  
 
Animal Studies 
MTD of ferroptocide 
The protocol was approved by the IACUC at the University of Illinois at Urbana-Champaign 
(Protocol Number: 14173). These studies used 10- to 12- week-old female C57BL/6 mice, that 
were purchased from Charles River. Ferroptocide was formulated in 100% PEG400 and given 
by i.p. All mice were monitored over the course of the study for signs of toxicity and weight loss. 
Pharmacokinetic assessment of ferroptocide 
The protocol was approved by the IACUC at the University of Illinois at Urbana-Champaign 
(Protocol Number: 14173). In these studies, 10- to 12- week-old female C57BL/6 mice 
(purchased from Charles River) were used. Ferroptocide was formulated in 100% PEG400. 
Mice were treated with ferroptocide (40 mg/kg) via i.p. with three mice per time point (15, 30, 
45, 60, 120, 240, 480, and 1440 min). At specific time points, mice were sacrificed, and blood 
was collected, centrifuged; the serum was frozen at -80℃ until analysis. The proteins in a 50 µL 
aliquot of serum were precipitated by the addition of 50 µL acetonitrile and the sample was 
centrifuged to remove the proteins. Serum concentrations of ferroptocide were determined by 
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reverse phase HPLC (Shimadzu Corporation, Japan). PK parameters were determined using 
GraphPad Prism Version 5.00 for Windows.  
 
4T1 syngeneic model  
The protocol was approved by the IACUC at the University of Illinois at Urbana-Champaign 
(Protocol Number: 17192). 9-week old, female Balb/C or SCID mice (Charles River) were 
lightly sedated with i.p. xylazine/ketamine/saline solution. Following sedation, 4T1 murine 
breast cancer cells suspended in chilled HBSS (100 µL of 4 x 106 cells/mL) were injected 
subcutaneously into the right flank of shaved and sedated mice using an insulin syringe. On day 
8 after inoculation, mice were randomized with 7 mice per group for vehicle or ferroptocide 
treatment. Vehicle (PEG400) or ferroptocide (50 mg/kg) was administered intraperitoneally as a 
PEG400 solution twice a week for 5 times. Tumor measurements were performed every 3 or 4 
days using a caliper and tumor volume was calculated using the equation (0.5 × l × w2). On day 
23 after the 4T1 cells inoculation, mice were sacrificed. Tumors were then surgically removed, 
and their mass was measured.  
Statistical analysis 
All statistical analysis was performed using an unpaired, two-tailed student’s t test where p < 
0.05 values were considered statistically significant.  
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Chapter 3: Personalized Therapy for Late-Stage Patients 
3.1 Personalized medicine approaches 
 
The ability to predict patient response to general cytotoxic or targeted therapeutics in the 
clinic remains a long sought but elusive goal. The overall objective in personalized medicine is 
to eradicate patient’s cancer via control of the tumor burden, reduction of cancer-related 
symptoms, increase of progression free survival (PFS) and overall survival (OS). The current 
clinical methods of providing individualized treatment (also known as precision medicine—
matching a drug to patient-specific features) encompass genomic and functional approaches.  
3.1.1 Genomic precision medicine 
 
The fundamental idea in genomic precision medicine involves identification of specific 
somatic alterations in cancer patients that can guide the development of targeted drugs for such 
abnormalities and improve patient’s life.  Somatic mutations are categorized as “driver” and 
“passenger” alterations and include point mutations, deletions, translocations, amplifications, and 
chromosomal aberrations.1,4 Drugs that target these alterations have been successfully developed 
and demonstrated patient benefit, thus giving rise to a new translational strategy in the clinic. 
One of the earliest examples, is imatinib that targets BCR-ABL kinase fusion, a translocation 
product in patients with chronic myeloid leukemia (CML).5 Lung cancers harboring epidermal 
growth factor receptor (EGFR) mutants are responsive to EGFR inhibitors such as erlotinib and 
gefitinib, as well as monoclonal antibodies.6,7 A dual tyrosine kinase inhibitor, Lapatinib,  
interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathway. Melanoma 
patients carrying BRAF V600E mutation are treated with vemurafenib as first line of therapy.8,9 
Other “druggable” mutations include microsatellite instability as a biomarker for sensitivity 
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against checkpoint blockers in colon cancer,10 synthetic lethal pairs such as BRCA and PARP-1 
inhibitors used in the clinic,11,12 TP53 mutation and checkpoint regulators (WEE1 and CHK1)13, 
synthetic lethality in KRAS mutant cancers,14 and many more mutations reported recently by 
Zhao and coworkers15 upon incorporation of a novel structural-genomics based strategy 
(SGDriver). 
Despite the many genomic advances that identified “druggable” mutations and enabled 
development of effective targeted-therapeutics, very few patients benefit from these drugs and 
modest clinical benefit has been 
identified primarily via non-
randomized retrospective studies.16-19 
For example, only one in five lung 
cancer patients harbor mutations in 
EGFR or ALK to respond to targeted-
chemotherapy.20-22 Multiple studies 
(SHIVA trial23, NCI-MATCH trial, 
MD Anderson Cancer Center trial24, 
and a more recent trial at Dana-Farber 
Cancer Institute25) have investigated 
the number of patients who bear an 
actionable mutation(s) and actually 
experienced an improved quality of 
life (QOL) upon enrollment in the 
targeted therapy arms. The results of these reports revealed that only 2.5% of 739- (NCI-
Figure 3.1. NCI-MATCH analysis of 739 submitted patient 
samples in May 2016.1 
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MATCH, Fig. 3.1) and 4.2% of 789- (MD Anderson Cancer Center) mutation-bearing patients, 
entered a genome-matched trial. While the reasons for these low patient enrollments change from 
trial to trial, all these reports emphasize the lack of and need for more potent targeted drugs. 
Notably, a large population of patients harbor numerous “non-druggable” aberrations that render 
them insensitive to targeted-drugs; thus, personalized treatment in the clinic cannot rely 
exclusively on genomic methods.  
3.1.2 Functional precision medicine 
Functional precision medicine is a complimentary approach to genomic medicine that 
involves monitoring of cancer cells upon exposure to a single drug or combination of drugs. 
Most of the commonly used chemotherapeutics in the clinic were discovered through some form 
of phenotypic-based observation, thus highlighting the importance and advantages of functional 
precision medicine.  
3.1.2.1 Historical functional approaches  
Initially developed in the 
1960’s, chemosensitivity and 
chemoresistance assays (CSRA) were 
the first functional assays that 
attempted to predict tumor 
response.26 CSRA consists of 
screening a panel of 
chemotherapeutics in primary tumor 
cells isolated from fresh biopsies or 
excised tumor samples. Since the 
Figure 3.2. Chemosensitivity and resistance assays are 
good predictors of patient response to chemotherapy in the 
clinic. Analysis was performed with data collected from 
retrospective studies from 1983–2016.2 
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1980’s, cytotoxicity assays have been incorporated in multiple platforms that are widely used by 
academic and clinical research groups to investigate the ability of CSRA to predict drug behavior 
in the clinic. These assays include: differential staining toxicity (DiSc), methyl thiazolyl-
diphenyl-tetrazolium bromide (MTT), adenosine triphosphate bioluminescence (ATP), 
fluorescein diacetate assay (FMCA), and microculture kinetic assay (MicK).  
According to a comprehensive 2017 meta-analysis that assessed all CSRA studies 
published from 1983–2016, there is a good correlation between CSRA results of different cell 
death assays and patient outcome (complete or partial remission) in the clinic. The prediction 
accuracy is as high as 90% for certain cancers (Fig. 3.2).2 This result suggests that ex vivo 
assessment of drugs is a reliable predictor of drug efficacy in patients. Furthermore, CSRA 
assays are incorporated in routine hospital analysis by clinicians in Japan, Switzerland, and 
Sweden.27-31 The analyses have helped guide treatment selection, improving overall survival, and 
lowering the cost of treatment for each patient by evading rounds of ineffective therapies.32 
Despite this progress, there remain significant challenges for a widespread adoption of 
this technology: 1) difficulty of culturing primary cells ex vivo, 2) isolation of low numbers of 
cells, 3) low yielding assays, 4) inadequate turnaround time for clinical decisions, and 5) lack of 
randomized clinical trials. In addition, drug assessment is conducted in 384-well plates, which 
require 1000–3000 cells per well, extending the growth time of primary cells in vitro and 
limiting the number of compounds that can be tested per each patient. Long culture times of 
primary cells ex vivo renders them susceptible to contamination and high mutation loads33,34 
severely limiting the ability of these cells to represent the original tumors, resulting in choices 




3.1.2.2 Recently developed functional assays  
 
Various methods as indicated in Table 3.1 have been developed to assess and measure 
drug exposure such that the information can be obtained in a clinically-relevant time frame. 
Despite the challenges described above, 2D cell culture models remain the mainstay of research 
and discovery. 3D cultures require weeks of expanding in culture—not favorable for clinical 
decision-making, and often select for viable clones thus lacking tumor representation.35 PDX 
models are valuable tools that capture a wealth of information about tumor biology; yet, their 
challenges include cost, time of establishment (4–8 months), and heterogeneity in tumor 
engraftment.36-38 BH3 profiling measures rapid induction of proapoptotic signals by drugs in a 
multiwell system and relates information within 48 hr of biopsy, thus circumventing the need for 
multiday culture of primary cancer cells.39-42 Lastly, CIVO is a novel technology that enables 
exposure of drugs directly to the tumor in vivo, preserving the tumor microenvironment, but it is 
costly and only applicable to superficial tumors.43-45 
In conclusion, genomic and functional methods complement each other and should be 
considered simultaneously when predicting the optimal drug regimen for cancer patients. Given 
that the clinical decision-making is time sensitive, only methods with a fast turnaround should be 
favored. However, genomic profiling is the only assessment currently used in the clinic in the 
US, while functional methods are still facing major obstacles despite their potential to identify 












3.2 Metastatic breast cancer no standard of care 
Metastatic breast cancer (MBC) is responsible for 90% of breast cancer deaths and has an 
overall 5-year survival rate of 22%.46 MBC is extremely challenging to treat due to tumor 
heterogeneity and the number/location of metastases. Regardless of the hormone receptor status, 
MBC patients are treated with cytotoxic chemotherapeutics (Fig 3.3). While several single–agent 
drugs have been 
approved for MBC, 
no clear consensus 
has emerged about 
which agent is 
superior or what drug 
to use for specific 
subtypes. 
Combination regimens have been extensively investigated, but due to overlapping toxicity 
Table 3.1. Methods in functional precision medicine and their timeframe. Abbreviations: PDX, patient-
derived xenografts; BH3, BH domain 3; CIVO, comparative in vivo oncology. Modified with permission 
from Letai and coworkers1. 
Figure 3.3. Chemotherapy is the backbone of treatment in breast cancer regardless of 
the receptor status. 
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profiles of candidate therapeutics, single–agent cytotoxic therapy remains the treatment of choice 
for MBC patients.47-49 Because there exists no standard-of-care chemotherapeutic treatment for 
MBC, there is a critical need to determine the best drug for each patient and to develop novel 
effective combination therapies. To address this need, we set out to conduct a non-interventional 
study (NIS) in collaboration with Carle Foundation Hospital.  
3.3 Non-interventional prospective study at Carle hospital  
A non-interventional prospective study is a prospective trial, where tumor samples are 
collected as patients receive treatment, and the results of the study do not interfere with treatment 
selection, procedures, data and patient recruitment, which continue to follow hospital 
regulations. NIS is advantageous compared to a retrospective study, as patients are followed real 
time throughout the course of their treatment and clinical information is readily accessible. Given 
the poor prognosis of 
metastatic breast cancer, 
varying efficacy of 
single-agent 
therapeutics, we 
conducted a NIS to 
inform clinician’s 
decisions about single–
agent selection for 
treatment of each MBC 
patient at Carle hospital, 
Figure 3.4. Treatment of metastatic tumor tissues in ex vivo cytotoxicity 
assays to determine the most sensitive agent or drug combination. 
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and to discover effective combination regimens that could have a strongly positive impact on 
advanced cancer treatment. 
The project consisted of an ex vivo cytotoxic screen of patient-derived tumor samples 
with each of the drugs and drug combinations approved for MBC. Our central hypothesis is that 
single agents and drug combinations identified via a functional assay will provide information on 
the optimal drug regimen for MBC patients and extend their overall survival. In addition, we 
envisioned correlating drug toxicity with mutational status identified via molecular profiling by 
RNA sequencing of the tumor samples, which is routinely performed on all tumor biopsy 
specimens. This information would then be organized in a bioinformatics database in accordance 
with the Health Insurance Portability and Accountability Act (HIPAA) regulations. This database 
will correlate molecular profile patterns with drug effectiveness and help predict treatment for 
patients in the future, as outlined in Fig 3.4  
While the primary 
focus of this project has 
been MBC, this strategy 
can also be extended to 
tumor samples from other 
metastatic diseases, 
specifically ovarian 
cancer (OC), which ranks 
fifth in cancer deaths 
among women. OC has 
poor prognosis, with 75% 
Figure 3.5. Types of samples collected from metastatic cancer patients at Carle 
hospital during 2016–2018 period. 
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of cases diagnosed in late stages and a 17% 5-year survival rate.50 Clinicians rely on carboplatin 
and paclitaxel as the postoperative standard of care for these patients; however, platinum 
resistance is rapidly acquired.51 Hence, clinicians still face the challenge of predicting the best 
chemotherapeutic out of several candidates. The fluorescent-based functional assay can support 
individualization of drug selection for these patients, thus resulting in higher response rates and 
improved overall survival.  
3.4 Results and analysis 
Recruitment of patients (>21 years old) for this study began in 2016 after obtaining an 
Institutional Review Board (IRB) approval. The cohort consisted of patients with solid tumors 
that had received specific procedures such as excisional biopsy/surgery, cytoreductive surgery, 
biopsy, thoracentesis, paracentesis, placement or draining of PleurX catheter.  
At the 10-patient mark, the data revealed that each patient sample was sensitive to a 
specific drug as expected, so the study was extended to all tumors besides breast cancer (Fig. 
3.5). To date, we have been able to access solid tumors and pleural effusion samples from 12 
different cancers totaling 47 patients. Isolation of primary cancer cells was successful for 28 out 
of 47 patients due to the low number of isolated cells, 7–10 days ex vivo culturing needed to 
generate triplicate data, and high susceptibility of sample contamination.  
A set of 9 drugs including FDA-approved drugs (5-fluorouracil [5-FU], cisplatin, 
etoposide, doxorubicin, gemcitabine, vinorelbine, taxol, and eribulin) and experimental drug 
PAC-1, was tested at 12 different concentrations in each of the isolated primary cancer cell lines. 
Cell viability was determined after 72 hr treatment using the Alamar Blue method, where 
resazurin dye converts to the fluorescent analogue, resorufin, in the presence of metabolically 
active cells. Half-maximum inhibitory concentration (IC50) values were calculated for each 
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compound and combined to build a training set, which can be utilized to determine compound 
sensitivity for future patients (Fig.3.6). This set will provide the benchmark of the average IC50 
value for each of these drugs in primary cancer cells. Comparison of results from future patients 
to this data set can potentially determine if a patient is a sensitive outlier or an inactive one for 
each of the tested drugs. Ideally, as the cohort expands, the training set can be modeled to each 
cancer type and ensure a higher prediction accuracy.  
Retrospective analysis of the entire cohort deemed challenging due to the late-stage of the 
malignancy for these patients resulting in patient death (32 diseased). Nevertheless, monitoring 
of patient response for three patients suggests that this ex vivo assay can accurately predict 
patient response to therapy. Metastatic breast cancer patient 10 (ER-PR-Her2/neu+) was 
Figure 3.6. IC50 data from 28 patients is used to build a training set. Cell viability was determined 
upon 72 hr treatment via Alamar Blue assay, 384 well. Red arrows indicate the inactive outliers 
while green arrows point at sensitive outliers. Data are representative of three biological replicates.  
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prescribed lapatinib (a dual tyrosine kinase inhibitor) and capecitabine (a 5-FU prodrug). The 
assay identified 5-FU as an inactive drug while taxanes, doxorubicin, vinorelbine, and PAC-1 
were found to be responders, thus the patient experienced disease progression (Fig 3.7 A). In the 
case of patient 13 suffering from carcinoma of unknown primary, taxol and carboplatin were the 
first line of treatment followed by FOLFOX (oxaliplatin, 5-FU, folinic acid) and avastin (VEGF-
A monoclonal antibody). The assay for this patient determined Pt-based compounds, doxorubicin 
and vinorelbine as the most active drugs; this patient displayed stable disease symptoms (Fig 3.7 
B).  
Lastly, patient 16 (peritoneal carcinomatosis) received the taxol/ carboplatin combination 
regimen and had an excellent response to therapy as shown in the CT scan images in Figure 3.7 
C; the assay revealed Pt-compounds, and doxorubicin as the best drugs. This limited analysis 
suggests that Alamar blue assay is reliable and offers value to researchers in the clinic to 
investigate drug sensitivity for each cancer patients. However, due to practical challenges such as 
the need for large numbers of cells (1.5–3 million per plate, 5 compounds) that results in 
extended ex vivo culturing of cells, and the high susceptibility to contamination, this method 
requires coupling to a more robust technology to resolve these critical issues.  
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Figure 3.7. Monitoring patient response in the clinic. (A) MBC patient 10 experienced progression of 
disease on capecitabine and lapatinib. (B) Patient with carcinoma of unknown primary with stable disease on 
taxol/carboplatin regimen followed by FOLFOX/ avastin. (C) PPC patient 16 responded to taxol/carboplatin 




3.5 Future technology PCEM 
One technology that could potentially address such a need is photonic crystal enhanced 
microscopy (PCEM), a label-free imaging technique, developed in the Cunningham lab. The 
PCEM instrument is a modified brightfield microscope that uses a line-scanning approach to 
measure the spatial distribution of peak wavelength value (PWV) across a photonic crystal (PC) 
surface with submicron spatial resolution for label-free imaging.3,52 PCEM is a single cell 
technology that measures cell adhesion on the surface of a photonic crystal and represents the 
results in a heat map format. Initial proof of concept studies were conducted with adherent ES-2 
(ovarian cancer) cells. Upon attachment, cells were subjected to treatment with a pro-apoptotic 
agent, Raptinal53, and 
cell death was monitored 
over time. As shown in 
Figure 3.8, cell death 
begins as early as 25 min 
and concludes at 7 hr 
(100% cell death) as 
observed in bright field 
(BF) panel and the 
reduced heat capacity in 
the PWV channel. These 
promising results inspired us to further explore the use of PC biosensors as a novel functional 
assay. However, fabrication of a larger photonic crystal chip that would enable screening of 
multiple drugs at various concentrations has proven challenging. Ongoing efforts are aimed at 
Figure 3.8. PCEM instrument schematic that incorporates parallel optical paths 
for broadband illumination with an LED for label-free imaging, and a laser 




troubleshooting the technical obstacles and optimizing the current process to implement this 
PCEM technology in the arsenal of ex-vivo functional assays.  
3.6 Conclusion and outlook 
This chapter focuses on historical and current methods available for personalized 
treatment medicine for cancer patients in the clinic. Ex vivo susceptibility assays are routinely 
used to inform selection of antibacterial therapy, thus the logical question remains as to why not 
utilize this strategy to cancer. The answer relies on the challenges of handling primary cancer 
cells: low cell numbers, ex-vivo culturing, tumor heterogeneity, and susceptibility to 
contamination. Regardless, there is an arsenal of genomic and functional approaches that address 
these challenges and have the potential to truly offer precision medicine in the clinic.  
Genomic and functional precision medicine are complimentary to each other, and yet 
only genomic methods are widely incorporated in routine clinical analysis. Multiple studies 
indicate the small number of cancer patients that benefit from targeted-therapeutics and draw our 
attention to the lack of potent drugs for “actionable” mutations. While the use of these “driver” 
mutations in designing targeted-therapies has been successful for limited patient populations; 
Figure 3.9. Proof of concept with PCEM technology. ES-2 ovarian cells were allowed to 
adhere to the chip surface and then treated with pro-apoptotic agent, raptinal (10 µM). 
Apoptosis was monitored over time. Data are representative images. 
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there is still an unmet need for the remaining majority of cancer patients. Functional methods can 
likely assist with these nonresponsive patients, but often lack the ability to yield information in a 
clinically-relevant time frame. 
The use of 2D cultures to study tumor biology has been the mainstay of discovery for 
years, and a retrospective analysis of all 2D assays with primary cancer cells revealed how these 
functional assays can be good predictors of patient response in the clinic, regardless of tumor 
type. This information can be tremendously helpful in the case of oncological malignancies 
without standard of care such as metastatic breast cancer or cancers that rely on clinician’s 
choice of treatment. 
We aimed to inform oncologists on the optimal treatment regimen for late-stage patients 
in the clinic by collaborating with Carle hospital in a non-interventional study. This NIS trial 
enabled us to recruit 47 patients over the course of 2 years and collect data for 28 patients. Data 
consisted of IC50 values of a set of 8 FDA-approved drugs and an experimental compound (PAC-
1) in primary cancer cells. The average IC50 values were then combined to build a training set 
that can serve as a benchmark of predicting patient sensitivity to each of this chemotherapeutics 
in the future. Furthermore, monitoring of a few patient outcomes revealed that the fluorescent-
based functional assay could accurately determine patient response. This promising result 
encouraged us to search for novel technologies requiring fewer number of cells that would 
enable data collection for all patients. One such technology is the single-cell resolution, label-
free imaging technology named PCEM (developed in the Cunningham lab at UIUC), which has 
demonstrated potential in initial studies. Ongoing efforts are focused on improving the high 




In conclusion, advancements in genomics and technology have tremendously increased 
our understanding of tumor biology and precision medicine. However, providing personalized 
treatment for all cancer patients in the clinic requires the use of complimentary approaches 
(genomic and functional assays). The sooner we implement these strategies side-by-side, the 
more likely we are to improve the overall patient survival and their quality of life. 
 
3.7 Methods and materials 
Primary Cells from Tumors 
 Upon obtaining fresh solid tumor samples from Carle hospital (minimum size of 1.2 
mm), tumor cells are obtained by enzymatic treatment with 0.1% collagenase and 50 U/ml 
dispase via incubation for 2 hours in a water bath. At the end of the incubation, cells are 
suspended in the appropriate growth media containing fetal bovine serum (FBS), and then 
filtered through a 85-µm nylon mesh cell strainer. Tumor cells are passed through filters to 
remove clusters and collected via centrifugation at 1000 rpm for 10 min. Trypan blue dye 
exclusion is used to check cell viability. Upon viability confirmation, cells are grown in the 
RMPI media containing 20% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg of 
streptomycin. These primary cells are then subjected to a fluorometric cytotoxicity assay based 
on resazurin reduction. 
 
Primary Cells from Pleural and Peritoneal Effusions 
Under sterile conditions, neoplastic effusions are transferred to 50 mL sterile tubes 
(Corning, Shiphol Rijk, The Netherlands) and centrifuged at 1200 rpm for 10 min. Once the 
supernatant is discarded, the cells are washed and re-suspended in complete medium. After 
evaluation of viability, the cells are seeded at a density of 3 × 106 cells/mL in 25 cm2 tissue 
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culture flasks (Corning) at 37 °C and 5% CO2. Culture medium is changed as needed. When 
cultures reach sub-confluence, cells are subcultured at a dilution of 1:3 until they begin to grow 
rapidly, and then serially subcultured at a dilution of 1:5 every three days. 
 
A Flurometric Cytotoxicity Assay 
 Resazurin is the active compound of the commercially available compound Alamar 
Blue.5 The resazurin assay can be used to quantify cell proliferation and cytotoxicity since the 
substance becomes increasingly fluorescent in the presence of metabolically active cells.6 To a 
384-well plate, 40 µL of 1.25X compound dilution or 1.25% DMSO-containing media is added 
(final volume of 1% DMSO in all wells). Concentrations of compounds tested ranges from 
100µM to 100 nM. On each plate at least 3 technical replicates are performed. Next, 10 µL of 
either a 100,000 cells/mL suspension are added to each well, yielding a final concentration of 
1,000 cells/well. To three wells in column 2, 1 µL of 10 mM doxorubicin (final concentration of 
200 µM) as positive control that should result in cell death are added. Plates are sealed with gas-
permeable seals and incubated at 37 ˚C for 72 h. At that time, 5 µL of Alamar blue (440 µM 
resazurin in sterile PBS) are added, the plates are incubated for 3–4 hours. Fluorescence is read 
on an Analyst HT or a Molecular Devices SpectraMax 3 (excitation = 555 nm, emission = 585 
nm, emission cutoff = 570 nm). Wells are normalized to the average of untreated wells (0% cell 
death). The data is plotted as compound concentration versus percent dead cells and fitted to a 
logistic-dose response curve using OriginPro (OriginLab, Northampton, MA). Hill Slope and 
Emax values can be obtained from curves fitted by OriginPro. The data is generated in duplicate 
or triplicate (dependent on cell numbers), and IC50 values, Hill slopes, and Emax values are 
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